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Abstract 
Nephrotoxicity is a common and serious side effect associated with cyclosporine 
A (CsA). Fish oil, rich in ro-3 polyunsaturated fatty acids (PUFAs), has been reported to 
be beneficial in alleviating the toxicities induced by CsA. Seal oil is another source of ro-
3 PUFAs. This project was designed to investigate the potential of using seal oil to reduce 
the nephrotoxicity of CsA. 
The cytotoxicity of CsA alone and in combination with seal oil emulsion, 
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), main PUF As in seal oil, was 
determined using the MTT assay and lactate dehydrogenase (LDH) leakage in LLC-PKl 
cell line. The effects of seal oil on the in vivo nephrotoxicity of CsA were investigated on 
two different experimental protocols: In the first experiment, CsA in 20% of seal oil or 
com oil emulsion was administered to SD rats at 50 mglkg/day p.o or 25 mg/kg/day i.p. 
for 28 days. In the second experiment, rats were kept on diets containing 7% sunflower 
oil, or mixture of 5.95% seal oil with 1.05% sunflower oil, four weeks prior to and during 
the four-week i.v. administration ofnormal saline (control) or CsA (15 mg/kg/day). 
The results of the in vitro studies revealed that DHA reduced the cytotoxicity 
induced by CsA. In vivo studies demonstrated that the nephrotoxicity associated with 
CsA was attenuated by the concomitantly supplemented seal oil. The possible mechanism 
of beneficial effects of seal oil may be exerted via modulating biosynthesis of 
prostanoids, leading to a higher ratio of prostaglandins to thromboxanes production, with 
a net favorable vasodilatory effect. 
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Chapter t, Introduction 
The focus of this work was to study whether seal oil, rich in long chain omega-3 
(ro/n-3) polyunsaturated fatty acids (PUFAs), could render protection against 
cyclosporine A (CsA) induced nephrotoxicity. A general overview about CsA, the 
characteristics of CsA-induced nephrotoxicity and the beneficial health effects of ro-3 
PUF As are discussed in this chapter. 
In the past two decades, the short-term success rate of solid organ transplantation 
including kidney, heart and liver reached unprecedented high levels. Eighty-five to ninety 
percent 1-year graft survival rate for kidney allograft has been achieved in most organ 
transplantation institutions all over the world, whereas the survival rates were about 60% 
in 1980 before the introduction of CsA. The survival rates for heart, liver, and lung 
transplantation have been similarly improved [Dunn et al., 1990; Beers et al., 1999]. This 
great achievement is mainly due to cyclosporine-based immunosuppressive regimens, 
and CsA became the cornerstone of modem immunosuppression for organ 
transplantation. Because of the success of CsA in solid organ transplantation, its usage 
was also extended to other refractory conditions, such as autoimmune diseases. Further 
research has shown that CsA also possesses anti-inflammatory [Hewitt, Black, 1996], 
antiproliferative [Blankenship et al., 2003], antiparasitic and other properties [Dambrin et 
al., 2000]. In cancer therapy, CsA is also used as are-sensitizer together with anticancer 
agents for the treatment of those patients who develop resistance to chemotherapy 
[Nielsen et al. 2002]. 
1 
1.1. Physicochemical properties of CsA 
CsA is a fungal metabolite and possesses potent immunosuppressive effect. It was 
first isolated from the fermentation of the fungus Beauveria nivea (formally 
Tolypocladium inflatum GAMS) [Csawell, A] in 1972 [Flechner, 1983]. It is a cyclic 
peptide containing 11 amino acids with a molecular weight of 1203 (Figure 1.1.). This 
structure includes a ~-hydroxyl, singly unsaturated C9 amino acid that was never before 
observed in nature at position number 1, as well as aD-alanine at position 8. Seven of the 
amino acids at position 1, 3, 4, 6, 9, 10, 11 are N-methylated that make CsA extremely 
hydrophobic [Dreyfuss, 1976]. 
Figure 1.1. Chemical structure of cyclosporine A (adapted from Helv Chim Acta 1976; 
59(5): 1480). 
2 
The compound is neutral and insoluble in water and n-hexane, soluble in ethanol 
and most other organic solvents and lipids. Therefore, it is usually administered by oral 
route in a lipid-based vehicle such as olive oil and peanut oil. Currently there are two 
commercial products ofCsA: Sandimmun® and Neoral® available for clinical use. 
1.2. Pharmacokinetic properties of CsA 
Upon oral administration, CsA is absorbed from the upper small intestine and its 
absorption is influenced by the rate of bile flow, food intake, concomitant medications 
and excipients used for administrating CsA. The absorption of CsA from the 
gastrointestinal tract is variable and incomplete, averaging 34%, with wide variability 
within and among patients, ranging 20-50% [Lemaire et al., 1990]. Initially, the mean 
absolute oral bioavailability from the first generation formulation of Sandimmune®, a 
solution of CsA in vegetable oil derivatives containing some other inactive excipients, 
was 25-30%, with up to 1 0-time inter-individual variations of CsA concentrations in 
blood [Fahr, 1993]. Then a new formulation named Neoral® was developed. With this 
formulation, CsA is incorporated into a microemulsion preconcentrate that contains 
lipophilic solvents, surfactants and ethanol. Because of the small particle size of the 
microemulsion and high degree of dispersion upon contacting with aqueous 
gastrointestinal fluid, absorption of Neoral® is significantly improved and more 
repeatable, with the oral bioavailability of 50-60%, lower inter- and intra-individual 
variations, and less food dependence [Mueller et al., 1994; Kovarik et al., 1994]. 
3 
In blood, about 2/3 of the CsA are bound to red cells and 1/3 to plasma 
lipoproteins. Only about 5-l 0% of the drug molecules are in a free fonn. Therefore, its 
therapeutic efficacy and toxicity may easily be influenced by lipoprotein levels and 
hematocrit. Due to its extreme hydrophobicity, CsA has a large volume of distribution 
throughout the body and high concentrations in adipose tissue, liver, and pancreas. The 
drug does not preferentially accumulate in kidney [Kahan, 1985a]. 
CsA is metabolized extensively to several metabolites by the hepatic and 
intestinal cytochrome P450 3A (CYP3A4) mixed function oxidase enzymes, with the 
parameters as follows: T112: 18 h, Tmax: 1.4 h (ranging 1-8 h); Vc (central compartment 
volume): 1 L/kg; Vz (distribution volume of the elimination phase): 5.8 L/kg [Baraldo et 
al., 2001]. Moreover, the exorption pump P-glycoprotein (P-gp) along the intestinal wall 
simultaneously pumps the absorbed drug molecules back to the lumen, preventing its 
accumulation inside the intestinal cells. These actions in a large part account for the low 
oral bioavailability of CsA. Because of the high dependence on cytochrome P450 
enzyme, CsA interacts easily with other concomitant administered medicines. Drugs that 
inhibit cytochrome P450 can increase the concentrations of parent CsA, and therefore 
cause side effects. On the other hand, drugs that induce the enzymes can decrease the 
concentrations of parent CsA and lead to reduction of the immunosuppressive effects. 
The majority of the metabolites are excreted in the bile and only a small amount through 
renal route into urine [Barone et al., 1996]. 
4 
1.3, Immunosuppressive p.rofiles of CsA 
In 1977, Borel et a!. [Borel et a!., 1977] reported the immunosuppressive effects 
of CsA. The clinical use of CsA to prevent organ transplantation rejection in oral or 
intravenous dosage fonns was approved by the Food and Drug Administration (FDA, 
USA) in 1983. Studies showed that CsA was effective in inhibiting both humoral and 
cell-mediated responses. In vivo, CsA strongly suppresses humoral immune response, 
which involves the production of antibody in response to specific antigenic stimulation, 
but it is the production of antibody by B-lymphocytes against T -cells dependent antigens 
that is strongly suppressed [Borel et al., 1994]. In addition, CsA also strongly suppresses 
cell-mediated immunity, which plays a major role in delayed-type hypersensitivity, 
autoimmune response, and the rejection of transplanted organs [Borel et al., 1977]. 
Moreover, preferential action of CsA on T-cells rather than B-lymphocytes had been 
demonstrated in mice, rat, and porcine cells [Burchardt et al., 1979]. 
CsA also inhibits cytokine production and its major immunosuppressive activities 
are exerted by blocking interleukine-2 (IL-2) synthesis [Schrieber, Crabtree, 1992]. IL-2 
is a lymphokine produced by activated helper T -cells when stimulated with IL-1. It has a 
wide spectrum of effects on immune responses. IL-2 affects clonal expansion of activated 
T -cells and natural killer cells (NK), and plays a key role in immune responses. 
Researchers [Bunjes et al., 1981] discovered that in human and mouse mixed lymphocyte 
reaction (MLR), which is an in vitro event reflecting host reaction to grafts, the 
production ofiL-2 was decreased in the presence of CsA. Decreased IL-2 synthesis leads 
to reduced T -cell activation or prolonged periods of T -cell unresponsiveness [Schwartz, 
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1990] and thus inhibits allograft rejection. Besides IL-2, CsA was also found to inhibit 
the production of various immunomodulators, such as interferon-y (IFN-y), IL-6, 
macrophage chemotactic factor (MCF), and macrophage activating factor (MAF) 
[Abbud-Filho et al., 1984]. 
The unique characteristic of CsA is that it acts specifically and reversibly on 
lymphocytes, and preferentially on T- rather than B-lymphocytes. Unlike other 
immunosuppressive agents such as Azathioprine and cyclophosphamide, CsA has no 
functional effect on granulocytes, thrombocytes, macrophages or phagocytic cells 
[Paavonen et al., 1981]. It was also found that CsA lacks of lymphocytotoxicity since it 
has no effect on the viability of unstimulated lymphocytes. Therefore, CsA acts early and 
reversibly on the triggering of lymphocyte proliferation, rather than interrupting the 
stimulation of antigen [White et al., 1979]. One ofthe major advantages ofCsA is lack of 
myelosuppression, which was a major limitation in using the conventional 
immunosuppressive agents. 
1.4. Mechanisms of action of CsA 
Study of the action of CsA at a molecular level demonstrated that its effect is 
dependent on binding to a substance to convert the drug to an active form, and undergo 
structural conversion. The substance that CsA binds to is a 16 kD cytoplasmic peptidyl-
prolyl isomerase named cyclophilin (Cyp) [Handschumacher et al., 1984]. The complex 
then binds to calcineurin (CaN) to form a pentameric unit to exert its 
immunosuppression. 
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CaN is a serine-threonine phosphatase with important regulatory effects on 
various genes, and requires calcium for its activation. In lymphocytes, CaN has a key role 
in the calcium-dependent pathway to the IL-2 gene. Normally, activation of a T -cell 
receptor at the surface of the cell causes increase of cytosolic Ca2+, which subsequently 
causes an activation of CaN. Then CaN dephosphorylates a number of substrates within 
the cell. When dephosphorylated, these substrates enter the nucleus and regulate the 
transcription of various genes. One of these CaN substrates is nuclear factor of activated 
T-cells (NF-AT), which is the first regulatory protein critical for promotion of DNA 
transcription of mRNAs that encode IL-2, which induces maturation and proliferation of 
helper T-cells, and other proinflammatory cytokines, including interferon-y and TNF-a 
[Johansson et al., 1990]. There was evidence suggested that CaN accompanies NF-AT 
into the nucleus, and itself participates in gene transcription by inhibiting the removal of 
NF-AT from the nucleus [Zhu et al., 1999]. Once CaN is bound by CsA-Cpy complex, its 
activity is inhibited, and the downstream dephosphorylation and transport of NF-AT is 
consequently obstructed, leading to the interruption ofiL-2 production [Liu et al., 1992]. 
In this way, by impairing IL-2 production, CsA selectively suppresses IL-2 driven 
proliferation of activated T -cytotoxic lymphocyte, while sparing T -suppressor cells. 
Besides the apparent inhibitory effects of CsA on CaN, the drug was also reported 
to enhance the expression of transforming growth factor-~ (TGF-~), a cytokine which not 
only has immunosuppressive effects, but also predisposes renal allografts to the 
progression of fibrosis [Shin et al., 1998]. 
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1.5. Renal effects of CsA 
Compared to other immunosuppressive agents, CsA reversibly inhibits only some 
classes of lymphocytes, and does not affect haemopoietic tissues [Rehacek et al., 1991]. 
Despite its unique advantage and immunosuppressive potency, the clinical use of CsA 
was limited by its frequent, diverse side effects. The reported side effects attributed to 
CsA include nephro-, neuro-, and hepatotoxicity, as well as hirsutism, gingival 
hyperplasia, hypertension and gastro-intestinal symptoms, among which nephrotoxicity 
and hypertension are the most serious and common [Myers, 1986; Klintmalm et al., 
1981; First et al., 1994]. It is well known that CsA causes two kinds of nephrotoxicity: 
dose-related decrease in renal function, and morphological changes in both human and 
experimental animals. 
The functional toxicity or acute nephrotoxicity includes dose-dependent reduction 
of renal plasma flow (RPF) and glomerular filtration rate (GFR), reflected by a decrease 
of creatinine clearance (Clcr) and a increase in blood urine nitrogen (BUN). This is 
associated with altered hemodynamics, which is largely thought to be due to CsA-
induced imbalance of production of vasoconstrictors and vasodilators that result in 
vasoconstriction of the afferent arterioles and glomerular capillaries [Remuzzi et al., 
1995; English et al., 1987]. The mechanisms of its action are still under debate. There are 
many vasoactive factors found to be involved in CsA-induced nephrotoxicity: increased 
production of vasoconstriction factors, such as endothelin (ET) [Bunchman et al., 1991; 
Darlametsos et al., 2000], thromboxane A2 (TXA2) [Rogers et al., 1988], noradrenaline 
(NA) [Duruibe et al., 1990], renin-angiotensin (R-A) [Siegl et al., 1982]; reduced release 
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of vasodilator prostaglandins E2, Iz (PGEz, PGiz) [Bennett et al., 1988a]; and nitric oxide 
synthase inhibition, of which the vascular alterations produced by CsA are very similar to 
those observed at early stages of atherosclerosis with decreased ability of the endothelium 
to secret nitric oxide [Gallego et al., 1993]. These effects were reported to be reversible 
upon dose reduction [Skorecki et al., 1992; Kahan et al., 1985b]. These acute 
hemodynamic effects may not be the only consequences of CsA on the kidney. In vitro 
studies revealed that CsA exerted direct toxicity on cultured bovine vascular endothelial 
cells, and the injury to the cells could induce the release of a number of vasoactive 
compounds [Zoja et al., 1986]. The injurious effects of CsA on cultured rat microvascular 
endothelial cells were practically due to inhibition of CsA on the regenerative response of 
the cells to injury, and the resultant alterations in prostacyclin production by these cells 
[Lau et al., 1989]. Altogether, vasoconstriction and endothelial cell damage may 
contribute to CsA-associated functional impairments. 
Structural or chronic nephrotoxicity may not be reversible and often is 
progressive, involving both renal arterioles and tubules. The morphological changes 
induced by CsA therapy in autoimmune disease patients, organ transplantation recipients, 
and experimental animals showed varied severity, including striped tubular atrophy, 
tubulointerstitial fibrosis, tubular vacuolization, tubular megamitochondria, 
microcalcification and afferent arteriolopathy [Mihatsch et al., 1988]. Mihatsch et al. 
[Mihatsch et al., 1995] stated that the landmark of cyclosporine nephropathy rests on the 
demonstration of particular vascular lesions in the afferent arteriole. Clinical studies 
found that the vascular lesions of chronic CsA nephropathy are not necessarily dose-
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related. According to Deray et al. [Deray et al., 1992], in clinical practice, even doses of 
CsA as low as 2-4 mg/kg given to patients can not completely spare the kidney from its 
injurious effects. Perico et al. [Perico et al., 1992] reported the impairment of renal 
hemodynamics from even a single dose of cyclosporine in chronically treated renal 
transplant patient. Therefore, some degree of renal vasoconstriction probably occurs in all 
patients who receive effective immunosuppressive therapy with CsA. Since CsA is a 
long-term used drug, especially for patients who have undergone organ transplantation, 
chronic cyclosporine nephropathy is of most concerned. It was defined by Mihatsch et al. 
[Mihatsch et al., 1995] as a clinical pathologic entity produced by exposure of the patient 
to cyclosporine, characterized by tubulointerestitial fibrosis in a striped pattern, beginning 
in the medulla and progressing to the medullary rays of the cortex. It is associated with 
degenerative hyaline changes in the walls of afferent arteriolar-sized blood vessels 
extending from the pro-glomerular area proximally up to the afferent arteriole. 
The mechanisms of structural nephrotoxicity may be different from those of 
functional impairments. It was reported that proximal tubular cell injury may play a 
major role in tubulointerstitial disease by releasing several vasoactive substance, influx of 
inflammatory cells into the interstitium, and fibroblast proliferation and matrix synthesis 
[Ong, Fine, 1994]. CsA has also been shown to activate apoptotic genes and increase 
apoptosis in tubular and interstitial cells, and CsA-induced apoptosis related with tubular 
atrophy and tubulointerestitial fibrosis [Yang et a!., 2002; Thomas et al., 1998]. 
Angiotensin n (Ang II) and transforming growth factor Pl (TGF-Pl) also play 
predominant roles in renal tubular morphological changes [Shihab et al., 1997; Young et 
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al., 1995]. Collectively, CsA may advance functional change to structural change by 
promoting two interrelated pathophysiological processes, sustained renal ischemia, 
enhanced apoptosis, and enhanced generation of hormones leading to chronic 
nephrotoxicity. The functional and structural nephrotoxicity are not distinct but 
interrelated processes with renal vasculature abnormality as their basic pathological 
pathway. 
1.6. Discovery of the beneficial effects of fish oil 
The epidemiological studies of Dreyeberg et al. [Dreyeberg et al., 1975] and 
Bang et al. [Bang et al., 1976] in the middle of 1970s demonstrated an association 
between the low prevalence of atherosclerosis in Greenland Inuit and their high intake of 
marine derived food sources. The incidence of coronary vascular diseases in Greenland 
Inuit is only 1110 of that of Danes or North American Whites, although their dietary lipid 
intakes are comparable. The distinct difference between their diets was found to be the 
composition of the dietary fat. The Danish diet contained twice as much saturated fat and 
more omega-6 ( ro-6) PUF As than the diet of Inuit; while Inuit consume 5-10 g omega-3 
(ro-3) PUPAs from fat of marine mammal and fish per day. Epidemiological studies also 
showed a low prevalence of cardiovascular diseases in people of the fishing and farming 
communities of Japan, who consume large amounts of marine fish in their diet [Hirai et 
al., 1980]. In a longitudinal study of risk factors and their relationship to chronic diseases, 
Kromhout et al. recorded the dietary habit of a group of men in the town of Zutphen, 
Netherlands and followed their mortality over a 20 years period. An inverse relationship 
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between fish consumption in 1960 and mortality from coronary artery diseases during 20 
years of follow-up was observed [Kromhout, 1985a; Kromhout et al., 1985b]. These 
benefits were thought to be ascribed to the unsaturated fatty acids composition of deep-
sea cold-water fish, and triggered immense interest of the role of unsaturated fatty acids 
in human health. 
1.7. Characteristics and classification of fatty acids 
Fatty acids are products of hydrolysis of fats. They are long chain organic acids 
that contain a long, nonpolar hydrocarbon chain with a single carboxyl group on one end 
and a methyl group on the terminal end. In biological systems, nearly all natural fatty 
acids contain an even number of carbon atoms, typically between 14 and 24. They are 
either saturated or unsaturated, containing one or more double bonds. In fatty acids 
containing two or more double bonds, the double bonds are mainly conjugated (-
CH=CH-CH=CH-). The double bonds of nearly all the naturally occurring unsaturated 
fatty acids exit in the cis geometrical configuration [Lehninger, 1982]. 
Fatty acids play two major physiological roles in mammalian tissues: a role in 
energy sources for fuel production and a role in structural components. Triacylglycerides 
(TAGs), esters of alcohol glycerol with three fatty acids molecules, function mainly as 
energy storage and fuel production in the cells. Another function of fatty acids is as 
building blocks of phospholipids and TAGs, and thus are important structural elements of 
cells. After intake into the body, instead of staying in free form in cells, fatty acids 
rapidly incorporate into the phospholipids of cell membrane, and consequently influence 
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membrane properties and function, such as membrane fluidity, ion transport and activities 
of membrane-associated proteins [Stubbs et al., 1990]. In addition, PUPAs in membrane 
phospholipids also serve as substrate for generating biologically active mediators upon 
stimuli [Cook, 1991]. The biological functions of fatty acids may vary with different 
chemical structures. There is evidence that the presence of eicosapentaenoic acid (EPA) 
or docasahexanoic acid (DHA) in the phospholipids of cell membranes may affect the 
physical properties of cell membranes and modify the function of membrane-bound 
proteins (receptors, transport pathways, and enzymes) by altering the microenvironment 
within which these proteins act [Dratz et al., 1986]. 
Fatty acids have been classified on the basis of their degree of saturation. 
Saturated fatty acids have no double bond; monounsaturated fatty acids have one double 
bond, and polyunsaturated fatty acids have more than one double bond. They are named 
on the basis of the length of the hydrocarbon chain, number and position of double bonds 
within the chain. Carbon atoms are numbered from the carboxyl carbon (carbon 1) to the 
terminal methyl carbon, which is known as co-carbon. The designation of omega (co or n) 
is used to give the location of the first double bond in a fatty acid counting from the first 
carbon atom at the terminal methyl of hydrocarbon chain. Taking ro-3 fatty acids for 
instance, its first double bond is located at the third carbon atom from the methyl end 
[Ackerman, 1995]. 
Figure 1.2. Illustration of fatty acid nomenclature. 
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In mammals, there are two distinctive classes of PUF As: ro-3 and ro-6. Unlike 
saturated and monounsaturated fatty acids which can be synthesized by all mammals, 
including humans, the long chain PUF As with double bonds more distal than the ninth 
carbon atoms counting from the terminal carboxyl of the hydrocarbon cannot be 
synthesized in the body. They are considered as the essential fatty acids, and therefore, 
must be intaken through the diet. The ro-3 family includes alpha-linolenic acid (ALA, 
Cl8:3 n-3), EPA (C20:5 n-3) and DHA (C22:6 n-3). ALA is the parent compound, 
existing in flax seeds, soybean, nuts and canola oil. Elongation and further desaturation of 
ALA can yield long-chain ro-3 EPA and DHA in animal and human very slowly; while 
both EPA and DHA can be obtained abundantly from marine source. They are originally 
formed in unicellular phytoplankton and multicellular sea algae and eventually pass 
through the food chain and become incorporated into the body of fish and higher marine 
species [Tinoco, 1982]. The ro-6 PUFAs come mainly from plant sources: vegetable, seed 
and nut oils such as com oil and sunflower oil. Arachidonic acid (AA, C20:4 n-6) is a 
long-chain ro-6 PUFA that is present in meat and plant sources, or is synthesized from 
linoleic acid (LA, Cl8:2 n-6). The structures ofthese PUFAs are listed in Figure 1.3. 
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Figure 1.3. Important PUFAs of the ro-6 and ro-3 classes (adapted from New England 
Journal ofMedicine 1988; 318(9): 550). 
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1.8. Fatty acids on eicosanoids metabolism and function 
Both AA and EPA serve as key precursors of eicosanoids in tissues. Eicosanoids 
are a family of biologically active substances produced by oxygenation of 20-carbon 
PUF As, in particular dihomo-y-linolenic acid (DGLA, C20:3 ro-6), AA and EPA. 
Eicosanoids include prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), 
lipoxins, hydroperoxyeicosatetraenoic acids (HPETE), and hydroxyeicosatetraenoic acids 
(RETE). The fatty acid precursors for eicosanoid synthesis are released from cell 
membrane phospholipids, usually by phospholipase A2 (PLA2) in response to a cellular 
stimulus. Because the membrane of most cells commonly contains predominantly AA, 
compared with DGLA and EPA, AA is usually the main precursor of eicosanoids 
production. AA produces the 2-series PGs (mainly PGI2, PGE2) and TXs (TXA2) through 
the cyclooxygenase (COX) pathway; and proinflammatory LTs (LTB4, C4, D4, E4) 
through the 5-lipoxygenase (LOX) pathway [Balter et al., 1989] (see Figure 1.4.). 
Eicosanoids are known to have vascular and haemostatic actions. In platelet, 
TXA2 is a major product of AA from the COX pathway. TXA2 has potent 
vasoconstriction and platelet aggregation effects. PGI2 is the main COX product of AA in 
endothelial cells. It possesses vasodilatory and antiaggregatory effects and can therefore 
counteract the actions of TXA2. PGI2 along with PGE2 are considered to be beneficial to 
renal disorders in that they are vasodilators of glomerular vessels, and thereby increase 
single nephron GFR and plasma flow [Plotnick, 1996]. 
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Figure 1.4. Synthesis of eicosanoids from the ro-6 precursor AA and the ro-3 precursor 
EPA (adopted from the New England Journal of Medicine 1988; 318(9): 
550). 
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Most of the beneficial effects attributed to fatty acids are believed to be the 
modulation of the ratio of the eicosanoid products. When ro-3 fatty acids are obtained 
from dietary sources, EPA and DHA are incorporated into the structure of phospholipids. 
EPA has the same structure as AA except for one additional double bond at the ro-3 
position. Thus, at the molecular level, EPA competes with AA in several ways: Firstly, it 
inhibits the formation of AA from LA [Holman, 1964]. Secondly, it competes with AA 
for the sn-2 position of membrane phospholipids, as AA is the predominant fatty acid 
occupying the 2-acyl position of phospholipids [Goodnight et al., 1982], and therefore 
the cellular and plasma levels of AA are decreased. Thirdly, EPA competes with AA as a 
substrate of COX to produce the 3-series of metabolites: TXA3 by platelets and PGI3 by 
endothelial cells. TXA3 is physically inactive and lacks vasoconstrictor properties [Siess, 
et al. 1980; Fischer, Weber, 1983]; while PGI3 is as potent as its 2-series counterpart to 
serve as a vasodilator [Fischer, Weber, 1984]. In fact, EPA does not seem to be a good 
substrate for TXA3 synthesis but allows normal or increased synthesis of PGI3 [Dyerberg, 
1986; Bunting et al., 1983]. In this way, the net effect is a change in the haemostatic 
balance toward a more vasodilatory state, with less platelet aggregation. 
The 4-series of LTs (LTB4, C4, D4, E4) produced from AA through the 5-LOX 
pathway have strong chemoattraction to circulating polymorphonuclear leukocytes and 
monocytes. They are involved in inflammatory, allergic, and immune responses 
[Samuelsson, 1983], and in the vascular response to ischemia [Mullane et al., 1987]. 
When EPA is incorporated into the phospholipids of cell membranes, it competes the 5-
LOX with AA, inhibiting the conversion of AA to the 4-series of LTs and producing the 
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less biologically active 5-series of LTs (LTBs, Cs, Ds, E5) in small amount. The 5-series 
of LTs compete with the 4-series of LTs at the receptor sites, and therefore reduce the 
chemoattractive effect of the 4-series of LTs [Goldman et al., 1983], In this way, 
supplementation of ro-3 PUFAs in the diet manifests the anti-inflammatory effects 
towards inappropriate recruitment of neutrophils to inflammation sites. 
1.9. Effects of ro-3 PUFAs on diseases and CsA-induced nephrotoxicity 
The beneficial effects of consuming ro-3 PUF As to the cardiovascular system had 
been widely recognized [Sassen et al., 1994]. Diets rich in ro-3 PUFAs have also been 
shown to improve inflammatory bowel disease [Stenson et al., 1992], rheumatoid arthritis 
[Geusens et al., 1994], and clinical status of cancer cachexia [Wigmore et al., 1996]. 
Since decreased GFR associated with reduced blood flow that may be caused by renal 
vasoconstriction has been recognized as a main cause of CsA-induced nephrotoxicity, 
and beneficial effects of ro-3 fatty acids on hemodynamics and the vascular system have 
been well documented, there has been considerable interest in the effect of dietary ro-3 
fatty acids supplementation on patients who undergo organ transplantation with CsA 
treatment. 
A clinical study with patients of normal kidney function that were given CsA for 
psoriasis showed that when CsA was combined with fish oil, the decrease of GFR was 
not as severe as that in CsA only group. Effective renal blood flow was unchanged for the 
CsA plus fish oil group, whereas that in the CsA without fish oil group decreased more 
than 10%. Total renal vascular resistance did not change for the group with fish oil 
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administration, but there was a nearly 20% increase of the total renal vascular resistance 
in the CsA only group [Stoof et a!., 1989]. In another study, patients who had undergone 
renal transplantation receiving stable CsA treatment were enrolled [Homan van ser Heide 
eta!., 1990]. In the group of patients given CsA with fish oil, GFR increased by nearly 
20%; effective renal blood flow increased by 17%; mean arterial pressure decreased by 
10%, and the calculated total renal vascular resistance decreased by 23%. However, no 
improvement of these parameters was observed in the group given CsA with com oil. 
Two years later, a similar study [Homan van der Heide eta!., 1992] was conducted and 
revealed that the administration of fish oil to patients receiving CsA for kidney 
transplantation significantly reduced the incidence of rejection and improved blood 
pressure and GFR. In this study, patients were admitted to a randomized double blind 
trial. Half of the patients were treated with 6 g fish oil per day during the first 
postoperative year, whereas the control group was treated with 6 g coconut oil for 3 
months, then it was stopped. One year after transplantation, the group supplemented with 
fish oil had higher values for GFR, lower mean arterial pressure and fewer cumulative 
rejection episodes (8 in fish oil group and 20 in the controls). One year graft survival was 
97% in the fish oil group and 84% in the control group. Bennett et a!. [Bennett et al., 
1995] also reported improved renal function, reduced blood pressure and graft rejection 
episodes in patients who underwent renal transplantation and received CsA regimen with 
fish oil supplementation, started after surgery. The results of these clinical studies 
revealed an attenuation of CsA-induced renal dysfunction when fish oil is supplemented 
to the patients receiving CsA treatment. 
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In animal experiments, Elzinga et al. [Elzinga et al., 1987a] showed pretreatment 
of rats with either fish oil or olive oil for 14 days, followed by administration of 50 mg/kg 
CsA for additional 14 days along with different oil treatment, resulted in decreased GFR 
in both CsA treated groups compared with nonnal control, but the mean value in rats 
administered fish oil was significantly higher than that of the olive oil group. A striking 
reduction in proximal tubular morphological change in the fish oil group was observed, 
accompanied with significantly lower renal cortical TXB2 content when compared with 
that of the olive oil group. Substituting fish oil for olive oil that is adopted for 
commercial products as a vehicle for CsA also reduced nephrotoxicity and TXA2 content 
in the kidney in Fischer rats during CsA therapy [Elzinga et al., 1987b]. Another study 
[Casas et al., 1995] using either fish oil or olive oil as vehicle for CsA administration 
found that CsA-induced nephrotoxicity and the decreased ratio of 6-keto-PGF1a/TXB2 
was greatly improved in the fish oil vehicle group, and renal function was directly 
correlated with eicosanoids production. 
Furthermore, when fish oil substituted for olive oil as a vehicle for CsA, fish oil 
potentiated the immunosuppressive activity of CsA, and thus enhanced the anti-rejection 
therapy of CsA [Kelly et al., 1989]. Levy and Alexander [Levy, Alexander, 1995] 
showed that Lewis strain rats receiving ACI strain cardiac allografts had a remarkable 
prolongation in allograft survival when they were fed a complete immunonutrient diet 
containing arginine and fish oil compared with the rats fed on standard diet (survival 
time: 275 ±53 days in fish oil diet versus 72 ± 7 days in standard diet). 
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According to both clinical and animal studies, it seems to indicate improved renal 
function and hemodynamics, and enhanced immunosuppressive effects when CsA based 
immunosuppressive regimens were administered in combination with long chain ro-3 
PUF As from fish oil. 
1.10. Immunosuppressive effects ofPUFAs from fish oil 
It is known that PGEz has a number of pro inflammatory effects, such as induction 
of fever and erythema, increasing vascular permeability and vasodilation. Since dietary 
fish oil leads to decreased PGEz and LTs production, it is supposed to have 
immunosuppressive effects. A number of reports about the actions of fatty acids on the 
immune responses of animals and humans also triggered considerable interests of 
researchers. Systemic investigation of a wide range of fatty acids in vitro has shown that 
fatty acids generally can suppress mitogen-stimulated proliferation of lymphocytes 
isolated from rat lymph nodes, spleen and lymphatic duct, from mouse spleen, or human 
peripheral blood [Tsang et al., 1977; Buttke, 1984]. Although both saturated and 
unsaturated fatty acids inhibit lymphocyte proliferation, unsaturated fatty acids exert 
greater inhibitory effect, and the greatest inhibition on proliferation is observed with the 
ro-3 EPA [Calder et al., 1991; Soyland et al., 1993]. It has been reported [Kelley et al., 
1985] that using dietary supplementation with fish oil as the exclusive source of lipid 
suppressed autoimmune lupus in MRL-lpr mice. A fatty acid component uniquely found 
in fish oil was speculated to be responsible for suppressed immunologic and/or 
inflammatory mediators of murine lupus by directly decreasing the production of PGE2, 
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TXB2 and PGiz. Animal feeding studies indicate that high levels of fish oil decrease NK 
cell activity, cytotoxic T lymphocyte activity, expression of IL-2 receptor on activated 
lymphocytes, lymphocyte proliferation and production of IL-2 and IFN-y [Fritsche et al., 
1990; Yaqoob et al., 1994; Nair et al., 2002]. The animal studies suggest that fish oil 
impairs cell mediated immunity and induces a shift in T -lymphocyte away from cell-
mediated immunity and chronic inflammation. 
Dietary supplementation with 1.6 g EPA and DHA per day to human volunteers 
for 3 weeks led to decreased expression of major histocompatibility complex (MHC) 
class ll on the surface of blood monocytes [Hughes et al., 1996]. Another study showed 
that supplementation of fish oil with > 2.4 g EPA and DHA per day can decrease the 
production ofTNF, IL-l and IL-6 by mononuclear cells [Meydani et al., 1991]. However, 
there are also reports of no effects on TNF, IL-2 production and NK cell activation of 
intaking 3.2 g EPA and DHA per day [Yaqoob et al., 2000; Schmidt et al., 1996]. 
Collectively, these studies indicated that high levels of fish oil supplementation to 
humans exert anti-inflammatory effects, and at least in some studies inhibit lymphocyte 
response. 
1.11. Seal oil: another source oflong chain co-3 PUFAs 
Harp seal is a marine mammal living in an ice-cold water environment. Blubber 
oil from harp seal is a rich source of long-chain co-3 PUF As. The original interest in 
studying seal oil is based on the observation of the low prevalence of cardiovascular 
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diseases in a population of Greenland Inuit whose diet included predominantly seal oil 
and meat [Kromann et al., 1980]. 
Studies demonstrated that seal oil is a superior source of ro-3 PlJF As compared to 
fish oil in several ways. Firstly, seal oil contains a substantial amount of the less well-
known ro-3 PUF A, docosapentaenoic acid (DP A, 22:5 ro-3). DP A is present at very low 
levels relative to EPA or DHA in fish oils. Seal oil can supply up to ten times more DP A 
than fish oils. In blood vessel walls EPA may actually be converted to DP A to exert its 
beneficial effects [Murphy eta!., 1997]. Japanese researchers [Kanayasu-Toyoda et al., 
1996] have shown that EPA exerted stimulating effects on endothelial cell migration via 
DP A, and DP A may act as a potent anti-atherogenic factor. Although it has been widely 
accepted that EPA is beneficial to the cardiovascular system by elevating the ratio of 
vasodilators to vasoconstrictors, this study indicated that DP A may be 10-20 times more 
powerful than EPA in this effect. Compared to EPA and DHA, DP A was also found to be 
the most potent PUF A in suppressing TXA2 formation by platelets which were exposed 
to collagen, thrombin, or AA [Akiba eta!., 2000]. 
Secondly, the intramolecular distributions of fatty acids in TAG of marine 
mammals differ from that in the TAG of fish. In seal oil, the ro-3 fatty acids are found 
mainly in the sn-1 and sn-3 positions of the TAG molecules, which is the same as in 
humans, whereas in fish oil the ro-3 fatty acids are mainly esterified in the sn-2 position 
[Puppione et al., 1992]. It is known that fatty acids at the sn-2 position of dietary TAG 
are retained during absorption process, which may be due to positional specificity of 
pancreatic lipase. This lipase hydrolyzes fatty acids at sn-1 and -3 positions, and produces 
24 
2-monoglycerol and free fatty acids. After hydrolysis products enter into intestinal 
mucosal cells, most of the free fatty acids are reesterified to 2-monoglycerol, and 
resynthesized TAG is incorporated into chylomicrons, which are secreted into lymph 
[Nelson et al., 1988]. Metabolic difference between fatty acids at the sn-2 and sn-1, -3 
positions of the TAGs after absorption has been thought to be a cause of the different 
physiological functions [Yamamoto et al., 1971]. 
A study conducted by Christensen et al. [Christensen et al., 1996] showed that 
rats administered seal oil had significantly higher load of ro-3 PUF As esterified in the sn-
1, -3 position of chylomicron TAG, compared with that of rats administered fish oil. 
Since TAG is degraded by sn-1, -3 specific lipoprotein lipase, the intramolecular fatty 
acid distribution of TAG in chylomicron may affect TAG metabolism in the systemic 
circulation. In another study [Yoshida et al., 1996], dietary lipids mainly containing seal 
oil or fish oil and having constant w-6/w-3 ratio of fatty acids were fed to rats for three 
weeks. Seal oil more effectively reduced plasma and liver TAG than fish oil. Ratio of the 
productions of aortic PGiz to platelet TXAz was significantly higher in rats fed seal oil 
than in those fed fish oil. The results suggested that the different intramolecular 
distribution of EPA and DHA in dietary fat affected lipid metabolism differently in rats. 
The difference of fatty acids distribution in TAG may also influence the absorption and 
distribution of ro-3 fatty acids in human [Nelson et al., 1988]. Although no clinical trial 
data is available based on the previous animal experiments, it may be speculated that the 
absorption and utilization of seal oil into the human body could be easier and more 
thorough than that of fish oils due to the difference of their chemical structures. 
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Thirdly, as seals are mammals, their metabolic and digestive systems filter out 
many natural impurities found in fish. Seal oils therefore provide a naturally purified and 
high quality source of ro-3 fatty acids. It was reported that the ro-3 PUF As content of harp 
seal oil is around 21% with DHA (9% ), EPA (7%) and a relatively high portion of DP A 
(4-6%) [Shahidi et al., 1996], which is higher than most fish oils. Moreover, Seal oil is 
virtually free of cholesterol, while many fish and fish oils are relatively high in 
cholesterol. In addition, because seal oil was extracted strictly from seal blubber, it is 
much purer than fish oils which are obtained by grinding, cooking and pressing fish offal, 
or whole fish [Ho]. 
Finally, seal oil is more stable than fish oil as a source of long chain PUF As. Fish 
oil is susceptible to oxidization, while seal oil is more resistant to natural oxidative 
processes. Experiments [Nakhla, 1997] showed that the extent of oxidization of ro-3 
PUF As in seal in vitro was less than half of that observed in fish oils. 
1.12. Studies of the effects of seal on on cardiovascular system 
Ikeda et al. [Ikeda et al., 1998] conducted a long term feeding of either seal or 
squid oil-rich fats that have different positional distribution of fatty acids to exogenously 
hypercholesterolemic rats for 160 days, and found that the AA levels in phospholipids of 
liver, platelet and aorta was lower in both marine oil groups than that of control, seal oil 
is more effective than squid oil; the platelet aggregation and platelet TXAz production 
induced by collagen were strikingly reduced in marine oils treated groups, with more 
pronounced action by seal oil; and seal oil-rich diet significantly increased the ratio of 
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aortic PGiz production to platelet TXA2. These results indicated that seal oil with the 
majority of its PUFAs at the sn-1, -3 positions, is more potent in modulating the 
production of prostanoids towards favorable vasodilation compared the sn-2 PUF As 
positioned fish oil. 
Besides studies on the effects of seal oil as well as fish oil in animal models, 
clinical studies with both normal and hypercholesterolemic subjects were conducted 
focusing on cardiovascular diseases. Vognild et a/. [Vognild et al., 1998] reported a 
clinical study of 266 healthy volunteers consuming 15 mL/day of cod-liver oil (CLO), 
whale blubber oil, a mixture of seal blubber oil and CLO, or a mixture of olive oil and 
CLO respectively for 12 weeks. Cardiovascular I thrombotic diseases associated 
parameters revealed that the consumption of various kinds of marine oils cause changes 
in platelet membrane towards anti-thrombotic effects, and the changes of platelet function 
are directly related to fatty acids composition in platelet membrane. There were no 
significant differences in triacylglycerols, total cholesterol, or high-density lipoprotein 
cholesterol (HDLC) observed. 
Another long term clinical study was also conducted to test the effects of dietary 
supplementation of seal oil and CLO on 120 subjects with moderate 
hypercholesterolemia [Brox et al., 2001]. The results showed that in people on seal oil 
diet or CLO diet for 14 months serum fatty acids composition changed significantly 
compared with control. Seal oil supplementation elevated serum EPA levels additionally 
30% higher than that of cod-liver oil. Both of the marine oil groups had lower whole 
blood platelet aggregation than control. No effects on serum total cholesterol, HDL 
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cholesterol, apolipoproteins, lipoproteins and TNF was observed in both marine oil 
treated groups. Both experimental animal and clinical studies revealed the promising 
beneficial effects of seal oil on the cardiovascular system, especially on platelet 
aggregation, by changing the composition of membrane fatty acids and the consequent 
changes of prostanoids production. 
Harp seals are abundant in Newfoundland and Labrador, and the beneficial 
medical effects of the superior long chain ro-3 PUF As in seal oil have attracted extensive 
interest from researchers. Nephrotoxicity is almost an inherent shortcoming of CsA. 
Despite the development of the new formulation Neoral®, which has been claimed to give 
improved bioavailability of CsA and less inter- and intra-patients variation, risk of 
adverse effects had been reported on switching to it, especially nephrotoxicity remains a 
medical challenge [Olyaei et al., 1997]. Based on the previous literatures, 
supplementation of fish oil in combination with CsA administration is beneficial to the 
toxicities associated with CsA immunosuppressive regimens. This project was 
undertaken to investigate the effects of supplementation of seal oil on CsA-induced 
nephrotoxicity in a rat model. Positive results of this study may be the key impetus 
leading to the development of novel formulation of CsA using seal oil as lipid phase. 
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Chapter 2@ Materials and Methods 
2.1. Materials 
2.1.1. Chemicals and reagents 
CsA was a generous gift from Huabei Pharmaceutical Corp., China. CsA injection 
(Sandimmune IV®, Ampoules, 50 mg/mL microemulsion) was a product of Novartis 
Pharm Canada Inc., Dorval, QC, Canada. Seal oil was generously provided by Caboto 
Seafoods Ltd., St. John's, NL, Canada. Com oil and sunflower oil were purchased from 
Walmart. Cremophor RH-40 was provided by Barnet Products Corp., Englewood Cliffs, 
NJ, USA. The ingredients used to prepare diets for animal studies including casein, 
cornstarch, dextrinized cornstarch, sucrose, fiber, AlN mineral mix and AIN vitamin mix 
were purchased from ICN Pharmaceuticals Inc., Montreal, QC, Canada. PUF As 
standards, mixtures of PUPAs with 14 to 22 carbon atoms chains, were obtained from 
Supelco Ltd. Supelco Park, Bellefonte, PA, USA. Fetal bovine serum (FBS, Cat. No: 
30071.03) was purchased from HyClone, Logan, UT, USA. Medium 199 (M199, Cat. 
No: M4530), 0.25% trypsin-EDTA solution (lx, Cat. No: T3924), 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl-tertrazolumbromide (MTT, Cat. No: M-2128), DHA 
and EPA (minimum 99% pure) were purchased from Sigma-Aldrich Canada Ltd., 
Oakville, ON, Canada. Nutriene™ Tocotrienols (Vitamin E, VE) was obtained from 
Eastman Chemical Com., Kingsport, TN, USA. All other chemicals used are at least of 
analytical grade and were purchased from Sigma-Aldrich Canada Ltd., unless otherwise 
indicated. 
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Diagnostics® Urea Nitrogen kit (Cat. No: 640) and Diagnostics® Creatinine kit 
(Cat. No: 555) were purchased from Sigma-Aldrich Ltd., St. Louis, MO, USA. PPR NAG 
Test Kit was purchased from PPR Diagnostics Ltd., London, UK. CYCLO-Trac® SP-
Whole Blood Radioimmunoassay for Cyclosporine kit was purchased from DiaSorin Inc., 
Stilwater, MN, USA. Bio-Rad DC Protein Assay reagents (Cat No: 500-0116) were 
purchased from Bio-Rad Laboratories Inc., Hercules, CA, USA. OXI-TEK Thiobarbituric 
Acid Reactive Substances (TBARS) Assay kit (Cat No: 0801192) was purchased from 
ZeptoMetrix Corp., Buffalo, NY, USA. Thromboxane B2 Biotrak Enzymeimmunoassay 
(EIA) System (Cat. No: RPN 220) and 6-Keto-Prostaglandin F1a Enzymeimmunoassay 
Biotrak (EIA) System (Cat. No: RPN221) were obtained from Amersham Biosciences 
Corp., Piscataway, NJ, USA. LDH Cytotoxicity Detection Kit (Cat. No: MK401) was 
purchased from Fisher Scientific, Ottawa, ON, Canada. 
2.1.2. Instruments 
EmulsiFlex®-CS high pressure homogenizer was purchased from Avestin Inc., 
Ottawa, ON, Canada. Delsa 440SX Zeta Potential Analyzer (Beckman Coulter®) was 
obtained from Coulter Electronics Inc., Hialeah, FL, USA. Heparinized microhematocrit 
capillary tubes were from Allied Corporation Fisher Scientific, Pittsburgh, P A, USA. Flat 
top microcentrifuge tubes were purchased from Fisher Scientific Ltd., Nepean, ON, 
Canada. Vacutainer tubes were obtained from BD, Franklin Lakes, NJ, USA. Centrifuge 
tubes were from Sarstedt Inc., Newton, NC, USA. Glass tissue grinder was from Kontes 
Glass Com., Vineland, NJ, USA. Cell culture flasks (25 cm2) were obtained from Falcon, 
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Franklin Lakes, NJ, USA 24 and 96-well plates were obtained from Corning Corp., 
Corning, NY, USA. Multichannel pipette was obtained from BrandTech Scientific Inc., 
Essex, CT, USA Microplate reader (Bio-Rad Model 550) was produced by Bio-Rad 
Laboratories, Hercules, CA, USA. Pulse amplifier (Model 29) was from 11 TC Inc., 
Woodland Hills, CA, USA The 2-channel recorder (LKB Bromma, Type 221 0) was 
obtained from LabX Com., Midland, ON, Canada. Centra-CL3 type centrifuge was 
provided by Thermo IEC, Needham Heights, MA, USA. Waters 2795 Alliance HT HPLC 
system and Micromass Quattro LC tandem mass spectrometer were from VCU Life 
Sciences, Richmond, VA, USA. C18 SecurityGuard cartridge (3mm x 4mm) was 
obtained from Phenomenex Inc., Torrance, CA, USA. Spectrophotometer (Beckman, 
DU62) was obtained from Beckman Instruments Inc., Fullerton, CA, USA. 
Spectrofluorophotometer (RF-1501, SHIMADZU) was obtained from Mandel Scientific 
Com., Guelph, ON, Canada. Hewlett Packard 5890 Series II gas chromatograph was 
purchased from Global Medical Instrumentation Inc., Albertville, MN, USA. 
2.1.3. Animals 
Male Sprague-Dawley (SD) rats were obtained from the Animal Care Services of 
Memorial University ofNewfoundland, St. John's, NL, Canada. 
2.1.4. Cells 
LLC-PKl cells (CRL 1392, passage 200-220) were purchased from American 
Type Culture Collection (ATCC), Manassas, VA, USA. 
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2,2. Preparation. and characterization. of CsA emulsions 
CsA is highly lipophilic and poorly water soluble. CsA emulsions in seal oil and 
com oil, as a drug delivery system, were prepared in this study. Emulsions with various 
amounts of surfactants (Cremophor RH-40 I Tween 80 = 2:1 (w/w) ranging from 0.3 to 
3.8% in 10% or 20% seal oil or com oil were prepared as follows: 
1. Under constant stirring, 50 mg of CsA powder was dissolved in 1 g of seal oil or 
com oil to prepare the 10% of oil emulsions, or in 2 g of oils to prepare the 20% of 
oil emulsions. 
2. Surfactants (Cremophor RH-40 I Tween 80 = 2:1 (w/w)) of 0.03, 0.06, 0.09, 0.12, 
0.15, 0.18, 0.21, 0.24, 0.27, 0.30, 0.33 and 0.38 g were added, respectively, and 
mixed thoroughly with the oil phase to form emulsion preconcentrates. 
3. Deionized distilled H20 was added dropwise to the preconcentrate to make the total 
weight to 1 0 g under constant stirring to form crude emulsion. 
4. The particle size of the crude emulsions thus prepared was reduced by passing 
through an EmulsiFlex®-CS high pressure homogenizer at 27,000 psi for four 
repetitions. 
The particle size of the final emulsions was determined by a Delsa 440SX Zeta 
Potential Analyzer. 
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2.3. 111- vivo studies 
2 . .3.1. Effect of different oils in the formulation of CsA emulsions on CsA-induced 
nephrotoxicity in rats 
Male SD rats weighing 200-230 g were housed under standard conditions, using a 
12 h light/dark cycle, with standard rat chow and tap water ad libitum. Rats were 
randomly divided into five groups as follows: 
e Group I (normal control): p.o. normal saline (NS) 10 mL/kg/day 
e Group ll: p.o. CsA in 20% of seal oil emulsion 50 mg CsA/kg/day 
e Group ill: p.o. CsA in 20% of com oil emulsion 50 mg CsA/kg/day 
• Group IV: i.p. CsA in 20% of seal oil emulsion 25 mg CsA/kg/day 
e Group V: i.p. CsA in 20% of com oil emulsion 25 mg CsA/kg/day 
The rats were administered NS or CsA in 20% of oil emulsions as indicated above 
for 28 days. The protocol used in this study was approved by Memorial University of 
Newfoundland Committee on Animal Care and Use, and adhered to the Guide to the 
Care and Use of Experimental Animals as issued by the Canadian Council on Animal 
Care. 
Blood samples were taken from the orbital vein with heparinized microhematocrit 
capillary tubes and 20-h urine samples were collected with metabolic cages one week 
prior to and once a week during the four-week i. v. administration ofNS or CsA in 20% of 
oil emulsions for 28 days. Systolic blood pressure (SBP) was also measured once a week. 
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2.3.2. Effect of dietary supplementation of different oils on CsA-induced 
nephrotoxicity in rats 
2.3.2.1. Preparation of the diets 
Two kinds of diets, Diet A-93G and Diet B-93G, were prepared and kept in sealed 
container at -20 ·c until use. Diet A-93G contained a mixture of 85% seal oil and 15% 
sunflower oil, whereas Diet B-93G contained 100% sunflower oil as their lipid, 
respectively. The two diets were otherwise identical in protein (supplied as casein), 
carbohydrates, fiber, minerals and vitamins content. The diets were designed to be 
isocaloric and isonitrogenous, and their compositions are listed in Table 2.1. [Reeves et 
al., 1993]. The procedure of diet preparation is as follows: 
1. Weigh all the solid ingredients and mix them up thoroughly in a big bowl. 
2. Weigh the oils and add to the powder mixtures while stirring at low-speed. 
3. Thoroughly mix all the components by high-speed stirring for 10 min with an 
electrical stirrer. 
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Table 2.1. Compositions of the various diets (AIN Purified Diets) (unit: g/kg diet) 
DietA-93G* DietA-93M# Diet B-93G* Diet B-93M11 I 
Casein (~85% protein) 200 140 200 140 
Cornstarch 397.5 465.7 397.5 465.7 
Dextrinized Cornstarch 132 155 132 155 
(90-94% tetrasaccharides) 
Sucrose 100 100 100 100 
Fiber 50 50 50 50 
Sunflower oil 10.5 6 70 40 
Seal oil 59.5 34 
AIN mineral mix 35 35 35 35 
AIN vitamin mix 10 10 10 10 
Choline bitartrate 2.5 2.5 2.5 2.5 
(41.1% choline) 
L-Cystine 3 1.8 3 1.8 
tert-butylhydroquinone 0.014 0.008 0.014 0.008 
* G stands for young (growing) rats and # M stands for old (mature) rats. 
35 
23,2.2. In vivo rat model of CsA-induced nephrotoxicity with dietary 
supplementation of different oils 
Based on the literature [Thliveris et al., 1991; Elzinga et al., 1987; Rogers et al., 
1988; Yamauchi et al., 1998], 3-week old male SD rats weighing 56 to 78 g were housed 
under standard conditions with free access to the diets we prepared and tap water. 
After three days acclimation to the new environment, the rats were randomly 
divided into four groups, and maintained on their respective diets for four weeks. To 
minimize variation, the diets for growing rats (Diet A-93G and Diet B-93G) were used 
along the entire experiment. From the fifth week, while the rats were still maintained on 
their respective diets, they received the 10-fold dilution of CsA injection (Sandimmune 
IV®) with NS, administered intravenously once a day from the tail vein at a dosage of 15 
mglkg/day for four weeks. Equal volume ofNS was administered to the rats as control as 
listed below: 
m Seal oil diet + NS injection (control): rats were fed seal oil diet (Diet A-93G) for 
eight weeks, during which starting from the fifth week, NS was administered i. v. for 
four weeks (n = 6). 
m Sunflower oil + NS injection (control): rats were fed sunflower oil diet (Diet B-
93G) for eight weeks, during which starting from the fifth week, NS was 
administered i. v. for four weeks (n = 6). 
m Seal oil diet + CsA injection: Rats were fed seal oil diet (Diet A-93G) for eight 
weeks, during which starting from the fifth week, CsA (Sandimmune IV®, 15 
mg/kg/day) was administered i. v. for four weeks (n = 8). 
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m Sunflower oil diet + CsA injection: Rats were fed sunflower oil diet (Diet B-93G) 
for eight weeks, during which starting from the fifth week, CsA (Sandimmune IV®, 
15 mg/kg/day) was administered i.v. for four weeks (n = 8). 
2.3.2.3. Collecting and processing of samples 
Blood and urine samples were taken one week prior to and once a week during the 
four-week i. v. administration of NS or CsA (15 mg/kg/day). The "Bleed Jugular Vein" 
method, a standard bleeding method accepted by the Animal Protection Organizations in 
the USA and Canada, was used to take around 0.6 mL blood sample from jugular vein. 
Briefly, a plastic table with 30° incline was used to lie the rat on its back, and the rat was 
restrained with a soft rope around its paw or wrist to stretch its arms straight out on the 
table. A plastic cap with holes was placed over the rat's head and twist slightly to the 
right or left side depending on which side the blood will be taken, twist to the left to take 
blood from the right, and vise versa. When the head being twisted, a triangular shape will 
appear on the neck, which can help locate the jugular vein. Then a sterilized syringe with 
a 23-gauge needle was inserted into the vein to take blood. 
A timed urine collection over 20-h was performed following blood sampling. Each 
rat was placed in a metal metabolic cage, with chow and tap water ad libitum. 
Blood samples were subjected to centrifugation at 3,000 g, 4 OC for 15 min. Urine 
samples were centrifuged at 10,000 g, 4 OC for 10 min. The supernatants were pipetted 
into 0.6 mL flat top microcentrifuge tubes. Aliquots of urine and serum samples were 
stored at -20 OC for analysis. 
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Systolic blood pressure (SBP) was also measured one week prior to and once a 
week during the course of administration of CsA or NS. 
At the end of the study, the rats were sacrificed by inhaling an overdose of ethyl 
ether. Blood samples were withdrawn by direct cardiac puncture. Four mL of blood was 
collected into Vacutainer tubes containing EDTA for determination of CsA 
concentration. Approximately 2 mL of the blood was added to 8 mL ice-cold NS in a 
centrifuge tube and mixed. Red blood cells (RBCs) were pelleted by centrifugation at 
3,000 rpm for 10 min, and the supernatant was discarded. The RBCs were then washed 
three times with NS and stored at -80 °C until further processed for analysis of fatty acid 
composition by gas chromatography (GC). 
The abdomen of the rats was opened by a midline incision and the abdominal 
aorta was cannulated retrogradely below the renal artery with an 18-gauge needle. With 
the aorta occluded by ligation above the renal artery and the renal vein opened by a small 
incision for outflow, the two kidneys were perfused in situ with 60 mL ice-cold NS till 
the color of the kidneys changed to pale. Kidneys were excised, halves of the left kidneys 
were fixed in buffered (phosphate-buffered saline (PBS), pH=7.4) 4% paraformaldehyde 
for histological processing and examination. The other halves of the left kidneys and the 
right kidneys were cut into smaller pieces, frozen in liquid nitrogen immediately, and 
stored at -80 °C for biochemical analysis. 
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2.4. Assessment of the effects of CsA 
2.4.1. Determination of blood urea nitrogen (BUN) 
The BUN test is used primarily to evaluate kidney function. Cells in the body 
need protein and blood carries proteins for use by cells. During digestion, protein is 
broken down to amino acids. Amino acids contain nitrogen, which is split off as NH4+ 
(ammonium ion), while the rest of the molecule is used to produce energy or other 
substances needed by cells. The ammonia is combined with other small molecules to 
produce urea in the liver as the end product of protein metabolism, which is then secreted 
into blood and excreted in urine by the kidney. Most renal diseases affect urea excretion 
so that the BUN level increases. 
For the first animal study protocol, the BUN levels at day 4, 11, 18 and 28 
following the commence of administration of respective drug regimen were measured 
spectrophotometrically by a Beckman Autoanalyzer-2 performed in the clinical 
biochemistry diagnosis lab at the General Hospital, Health Care Corporation of St. John's 
(HCCS), St. John's, NL, Canada. 
For the second animal study protocol, the BUN levels were monitored one week 
prior to and once a week during the four-week i.v. administration of NS or CsA (15 
mglkg/day) by a clinically used colorimetric method using a Diagnostics® Urea Nitrogen 
kit. The principle is that urea is hydrolyzed by urease to ammonia and carbon dioxide. 
Ammonia then reacts with alkaline hypochlorite and phenol in the presence of a catalyst, 
sodium nitroprusside (Na2Fe[CN]sNO .. 2H20), to form indophenol [Fawcett, Scott, 1960; 
Hom, Squire, 1967]. The concentration of ammonia is directly proportional to the 
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absorbance of the blue color of indophenol, which can be measured 
spectrophotometrically at 570 nm. 
H2N"'- Urease 
C=O +H20---/ 
H2N 
Urea 
2NH3+COz 
NH3 +ocr + 2 OH Nitroprusside o- Sodium 
Phenol 
The testing procedure is as follows: 
Indophenol (blue) 
1. To each properly labeled test tube, 100 J..!L of urease solution was added. 
2. To the blank, standards, or tests tubes, 5 J..!L of H20, urea nitrogen standards, or test 
samples were added respectively. Mix contents by gently swirling. 
3. Place tubes in a 37 ·c water bath for 10 min allowing urea to be hydrolyzed to 
ammo rna. 
4. Add 200 J..!L of phenol nitroprusside solution, 200 J..!L of alkaline hypochlorite solution 
and 1 mL ofHzO to each tube in order. Mix after each addition. 
5. Allow tubes to develop color at room temperature for 30 min. 
6. After color development, 300 J..!L of solution from each tube was added to wells in a 
96-well plate, and the absorbance was read by a microplate reader at 570 nm. 
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2.4.2. Measurement of creatinine clearance (Clcr) 
Clcr is another measurement of kidney function. Creatinine, a waste product in the 
blood, is created by the normal breakdown of muscle during physical activity. Healthy 
kidneys remove creatinine from the blood and it is finally excreted out of the body in the 
urine. Creatinine accumulates in the blood when the kidney does not work properly. The 
Clcr test shows how fast the kidney removes creatinine from the blood, i.e. the amount of 
blood "cleared" of creatinine per time period. Clearance is commonly measured in 
milliliters per minute (mL!min). The determination of creatinine in both serum and a 
timed collection of urine is necessary [Bowers, Wong, 1980]. 
Clcr was calculated as follows: 
Clcr (mL!min) =(urine creatinine I serum creatinine) x urine Vol. (mL) I [time (h) x 60] 
For the first animal study protocol, the Clcr levels were measured 
spectrophotometrically usmg a Beckman Autoanalyzer-2, performed in the clinical 
biochemistry diagnosis lab at the General Hospital, HCCS, at day 4, 11, 18 and 28 
following the start of administration of CsA in 20% of oil emulsions. 
For the second animal study protocol, serum and urine creatinine concentrations 
were measured one week prior to and once a week during the four-week i. v. 
administration of NS or CsA (15 mg/kg/day), with a colorimetric method using a 
Diagnostics® Creatinine kit. The principle of this test is that yellow/orange color forms 
when creatinine reacts with alkaline picrate. The color derived from creatinine is 
destroyed at acidic conditions. The difference in color intensity measured at or near 500 
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nm before and after acidification is proportional to creatinine concentration [Heinegard, 
Tiderstrom, 1973; Cook, 1975]. 
In our study, this colorimetric reaction was carried out in a 96-well plate, instead 
of in cuvets as suggested by the producer, because of the large number of samples. The 
procedure is as follows: 
1. To the blank, standard and test wells, 25 JlL of H20, a series of dilutions of standard, 
serum and 12-fold diluted urine samples were added to the corresponding wells. 
2. To each test well, 250 JlL of alkaline picrate solution was added. The plate was 
shaken by a microplate shaker for 10 min at room temperature. 
3. The initial absorbance was read at 490 nm by a microplate reader. 
4. To each well, 8.3 JlL of acid reagent was added. The plate was shaken for 60 min at 
room temperature. 
5. The final absorbance was read at 490 nm. 
Absorbance of creatinine = Initial Absorbance - Finial Absorbance 
2.4.3. Measurement of urine volume 
The volumes of urine samples collected over 20 h with metabolic cages were 
measured using a volumetric flask. The mean values were obtained from 6-8 animals in 
each group. 
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2.4.4. Determination. of protein contents in. urine 
Protein concentrations in urine samples collected over 20 h were determined by a 
colorimetric assay using the Bio-Rad DC Protein Assay reagents. The reaction is a 
modified Lowry assay, which is based on the reaction of protein with an alkaline copper 
tartrate solution and Polin reagent. The amino acids tyrosine and tryptophan, and to a 
lesser extent, cystine, cysteine, and histidine, react with copper in alkaline medium. The 
copper-treated proteins affect the reduction of the Polin reagent by loss of 1, 2, or 3 
oxygen atoms. The consequent reduced products have a characteristic blue color which 
can be measured at 630-750 nm [Peterson, 1979]. The procedure of determination is as 
follows: 
1. Pipette 5 !J.L of H20, protein standards (0.2- 1.5 mg/mL) and urine samples into 
the blank, standard and test wells in a clean and dry 96-well plate. 
2. Add 25 ~-tL of Regent A into each well. 
3. Add 200 ~-tL of Regent B into each well and mix for 5 sec with the mixing function 
of microplate reader. 
4. After 15 min, a blue color developed, and the absorbance was read at 640 nm by the 
microplate reader. 
2.4.5. Measurement of urinary N~Acetyl-1 ~p-D~glucosaminidase (NAG) 
Urinary NAG is recognized as a sensitive and reliable indicator of the presence of 
renal disease. The NAG test was reported to offer a greater sensitivity to reflect kidney 
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abnormality than the Clcr test, because serum creatinine levels do not become abnormally 
elevated until 50% of renal function has been lost [Price, Whiting, 1992]. 
The NAG levels in urine samples of rats were measured by a colorimetric 
procedure using a commercially available PPR NAG Test Kit. This test is based on the 
hydrolysis of its substrate (2-Methoxy-4-(2' -nitrovinyl)-phenyl 2-acetamido-2-deoxy-~­
D-glucopyranoside, (MNP-GlcNAc)) by the enzyme NAG to release a phenolic 
compound (2-Methoxy-4-(2' -nitrovinyl)-phenol). In the presence of alkaline buffer, this 
compound produces a red color in proportion to the hydrolysis created by the levels of 
NAG present [Yuen eta!., 1984]. According to the direction, the procedure is as follows: 
1. To each properly labeled test tube, 50 JlL of H20, NAG calibrant solution, or urine 
samples were added to the corresponding tubes of blank, standards, or tests at strict 
timed intervals. 
2. To each tube, 750 J.tL of Reaction Solution 1 was added. The content was mixed and 
incubated in a 37 OC water bath for 30 min. 
3. To each tube, 250 JlL of Color Development Buffer was added. Mix the content and 
place the tubes at room temperature for 10 min. 
4. The absorbance was read at 505 nm using a Beckman Spectrophotometer DU62. 
All the adding of samples and reagents, reading of absorbance are at the strictly timed 
intervals. Enzyme activity is expressed as Jlmol/h. 
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2.4.6. Measurement of SBP 
SBP of conscious restrained rats was measured using the tail plethysmography 
method. For this measurement, rats were placed in a quiet, temperature-controlled 
environment (33 OC) to prewarm for 30 min, so that they were in a relaxed mood when 
measuring the blood pressure. A tail cuff with a light sensor connected to a pulse 
amplifier was placed as proximal as possible and four to six blood pressure readings were 
recorded using a 2-channel recorder. For the first animal study protocol, SBP was 
measured prior to and at day 8, 15, 22, and 27 following the administration of CsA in 
20% oil emulsions. For the second animal study protocol, SBP was monitored one week 
prior to and once a week following the start ofi.v. administration ofCsA (15 mglkg/day) 
or NS. The SBP reported are the average of four to five measurements. 
2.4.7. Assessment of growth 
It had been reported, and observed in our experiments that administration of CsA 
to rats suppressed their growth. The body weight (BW) of rats was recorded daily, and 
the mean value of each group was calculated once a week. 
2.4.8. Renal histological change 
For the second animal study protocol, immediately after sacrifice of the rats, the 
kidneys were removed and bisected. Portions that were fixed in 4% paraformaldehyde 
were processed for light microscopic examination by standard histologic techniques. 
Paraffin sections were cut to 4 J.Lm thicknesses, and stained with hematoxylin and eosin 
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(HE). The severity of cortical and medullary injury was assessed by a pathologist 
without knowledge of the treatment group. 
2.4.9, Measurement of CsA concentration in blood 
In the first in vivo study, the CsA concentrations in whole blood taken 24 h after 
the last dosing were determined using CYCLO-Trac® SP-Whole Blood 
Radioimmunoassay for Cyclosporine kit. It was measured by the Renal Lab of the HCCS. 
In the second in vivo study, the CsA levels in whole blood were determined by 
liquid chromatography-Tandem mass spectrometry (LC-MS). 
Briefly, a CsA stock solution (0.5 g/L) was prepared in methanol, and a set of 
calibrators (25, 50, 100, 200, 400, 800 J!g/L) was prepared by two-fold diluting of the 
stock solution. Ascomycin (100 !lg/L) was used as an internal standard. 
To a 100 J.!L of whole blood sample, 100 J!L of acetonitrile containing ascomycin 
internal standard was added. Then the samples were deproteinised by adding 40 IlL of 0.1 
M ZnS04 solution. After vortex mixing and centrifugation at 13,000 g for 5 min, the 
clear, colorless supernatant was transferred to an autosampler vial for further analysis. 
HPLC: Chromatography was performed on a Waters 2795 Alliance HT HPLC 
system. The processed whole blood samples were analyzed using an on-line solid phase 
extraction technique. Ten IlL samples were injected into a C18 SecurityGuard cartridge 
(3 rnm x 4 mm) maintained at 45 OC and equilibrated with 50% aqueous methanol 
containing 2 mM ammonium acetate and 0.1% fomic acid at a flow rate of 0.5 mL/min. 
After washing for 0.1 min, the methanol concentration was maintained to 100% over 1 
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mm to elute the test samples. The cycle time from injection to injection was 
approximately 2.5 min. The elute was connected directly to the electrospray probe of the 
mass spectrometer. 
MS: A Micromass Quattro LC tandem mass spectrometer fitted with a Z Spray ion 
source was used for analyses. The instrument was operated in electrospray positive-
ionization mode and was directly connected to the HPLC system. CsA and ascomycin 
were detected using multiple reaction monitoring (MRM) for the ammoniated species 
[M+~t. The tuning parameters for CsA involved monitoring the m/z 1220>1203 
transition at 20 eV collision energy using argon gas. For ascomycin the m/z 809.4>756.4 
transition was monitored using a 26 e V collision energy. Cone voltage was held at 65 V 
throughout with RF lens setting at 35.0. System control and data acquisition were 
performed with MassLynx NT 3.4 software with automated data processing by the 
MassLynx Quantify program. Calibration curves were constructed using linear least-
squares regression with llx weighting. 
2.4.10. Measurement of :renal lipid peroxidation 
Lipid peroxidation in kidney was assessed by detecting malondialdehyde (MDA), 
the lipid peroxidation product. An MDA molecule form a 1:2 adduct with thiobarbituric 
acid and produces a compound, 
sy:,xN~ OH HO~NYH 
N~ ~ ~ N 
CH-CH=CH 
OH OH 
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which can be measured spectrophotometrically. The MDA content m 10% kidney 
homogenate of rats was measured with an OXI-TEK TBARS Assay kit. 
Preparation of 10% kidney homogenate: in a glass tissue grinder that sat in an ice 
bath, around 100 mg kidney tissues was added 0.4 mL, 100 mM ice-cold potassium 
chloride containing 3 mM EDTA, and homogenized. Additional 0.6 mL of the potassium 
chloride buffer solution was used to wash the grinder 3 times. The combined tissue 
homogenate was centrifuged at 10,000 g, 4 OC for 10 min. The supernatants were 
withdrawn and stored at -20 OCto minimize oxidation [Wang, Salahudeen, 1994]. 
MDA content in the supernatant of kidney homogenate was measured as follows: 
1. To each properly labeled test tube, 50 j.tL of HzO, MDA standards, or test samples 
were added to the corresponding tubes of blank, standards, or tests. 
2. SDS solution 50 j.tL was added to each tube and swirled to mix. 
3. TBA reagent 1.25 mL was added to each tube and mixed. 
4. Cover each tube with a glass marble and incubate at a boiling water bath for 60 min. 
5. After cooling to room temperature in an ice bath, the samples were centrifuged at 
3,000 g for 15 min. 
6. The absorbance of supernatants were read by a spectrofluorophotometer with 
excitation wavelength of 530 nm, emission wavelength of 550 nm, and the sensitivity 
be set at high with a slit width of 10 nm. 
The protein concentration in kidney homogenate was determined by DC protein 
assay as stated in section 2.4.4. The MDA levels were presented as nmol /mg protein. 
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2.4.11. Measurement of urinary thromboxane B2 (TXlh), 6-keto-prostaglandin F la 
(6-keto-PGFla) 
For the second in vivo study protocol, urinary TXBz and 6-keto-PGF1a levels of 
the last 20-h urine collection (at the fourth week of administration of CsA) were analyzed 
using direct competitive binding enzymeimmunoassay (EIA) kits: TXB2 Biotrak EIA 
System and 6-keto-PGF1a Biotrak EIA System. 
The assay is based on the competition between unlabelled 6-keto-PGF1a and a 
fixed quantity of peroxidase labeled 6-keto-PGF1a, for a limited number of binding sites 
on a 6-keto-PGF1a, specific antibody. With a fixed amount of antibody and peroxidase 
labeled 6-keto-PGF1a the amount of peroxidase labeled ligand bound by the antibody will 
be inversely proportional to the concentration of added unlabelled ligand. Since the 
peroxidase ligand that is bound to the antibody is immobilized on to polystyrene 
microplate wells that are precoated with secondary antibody, any unbound ligand can be 
removed from the well by simple washing procedures. The amount of peroxidase labeled 
6-keto-PGF1a bound to the antibody is determined by addition of a tetramethylbenzidine 
(TMB) substrate. The reaction is stopped by adding an acid solution, and the resultant 
color can be read at 450 nm. 
6-keto-PGF1a ~ Rabbit anti-6-keto-PGF1a ~ 6-keto-PGF1a-Peroxidase + Tr 
Measure O.D. 
The concentration of unlabeled 6-keto-PGF1a in a sample is determined by interpolation 
from a standard curve. 
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According to the directions, the measuring procedure is as follows: 
1. Set up sufficient strips of wells and add 50 11L of buffer, standards, and test samples 
to the corresponding wells of blank, standards and tests; 100 11L of buffer for the 
non-specific binding. 
2. Add 50 11L of antiserum to all wells except for the non-specific binding. 
3. Add 50 11L of 6-keto-PGF1a Peroxidase conjugate into all wells except for the blank. 
4. Incubate at room temperature for 1 h while samples were kept shaking by a 
microplate shaker. 
5. Aspirate and wash all wells four times with 400 11L of washing buffer each time. 
6. Add 150 11L of enzyme substrate TMB to all the wells and shaking for exactly 15 min 
at room temperature. 
7. Add 100 11L of 1.0 M sulfuric acid to all the wells, mix the content and the absorbance 
was read by microplate reader at 490 nm within 30 min. 
The principle and operation ofTXB2 assay are the same as that of6-keto-PGF1a. 
2.4.12. Analysis of fatty acid compositions in diets and erythrocyte membrane of 
rats 
The fatty acid compositions in erythrocyte membrane of rats and the two diets 
containing different oils were analyzed by GC. 
The RBCs and diet samples were homogenized with a glass grinder and total 
lipids were extracted using a modified Folch wash procedure [Folch et al., 1957] as 
follows: 
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1. Add 20 mL of CHCb and 10 mL of MeOH to the RBCs pellet m grinder, 
homogenize for 2 min. 
2. Suction filtration---collect filtrate into the grinder, keep the liquid portion. 
3. Add another 20 mL ofCHCh and 10 mL ofMeOH to the grinder, homogenize for 3 
min, and suction filtrate. 
4. Wash with 20 mL ofCHCh and then 10 mL ofMeOH. 
5. Transfer the collected liquid portion to a graduated cylinder with a glass stop. 
6. Add V4 of the total volume of 0.88% KCl aqueous solution, shake thoroughly and 
allow to settle. 
7. Remove top layer by aspiration, add Y4 of the bottom layer (organic layer) volume of 
H20-Me0H (1:1, v/v), shake and settle. 
8. Remove top layer by aspiration, transfer to beaker and blow down with nitrogen 
(Nz). 
9. Resuspend with 2 mL ofCHCh and store in a small vial for transmethylation. 
Isolated lipid samples were transmethylated using 2 mL Transmethylation 
Reagent (94% MeOH, 6% aqueous HCl) and a few crystals of hydroquinone in a 
transmethylation vial at 60 T for 2 h. Fatty acid methyl esters thus formed were 
separated by GC using an Omegawax™ 320 capillary column (30m x 0.32 mm x 0.2 J.!m 
thickness) in a Hewlett Packard 5890 Series II gas chromatograph equipped with a flame 
ionization detector. Separation was performed isothermally at 200 OC, with helium as the 
carrier gas at a flow rate of 1 mL/min. Identification of the peal<:s in the chromatograms 
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was made by comparison of retention time with known standards composed of different 
fatty acids. The percent composition data were normalized as: 
transformed data == arcSin (I area%/100) * 100 
The transformed data were employed to conduct the statistical analysis. 
2.5. In vitro studies 
To further investigate the effects of seal oil on the nephrotoxicity associated with 
CsA, in vitro studies were also conducted. LLC-PKl, a pig proximal tubular epithelial 
cell line, was used as a model of the proximal tubule for the study of renal cytotoxicity 
induced by CsA. 
LLC-PKl cells were grown in Ml99 supplemented with 3% FBS at 37 °C, 5% 
C02 as suggested by ATCC. CsA that used for the in vitro study was Sandimmune N® 
microemulsion containing 50 mg CsA /mL. Non-medicinal ingredients in the formulation 
include: dl-a-tocopherol, ethanol, hydrogenated castor oil, maize oil, and propylene 
glycol. The CsA microemulsion was diluted with the cell culture medium to appropriate 
concentrations shortly before experiment. 
Seal oil was prepared as a 10% seal oil emulsion with 1.2% Lipoid 80 as 
surfactant, 2.25% glycerol, and 2.0 !lM KzHP04, 4.0 !lM EDTA-2Na buffer as the 
aqueous components. The emulsions were prepared as described earlier (Section 2.2.), 
and sterilized by autoclaving at 121 °C for 30 min prior to use. 
DHA, EPA and VE were dissolved in dimethylsulfoxide (DMSO) (50 mg/mL), 
and then diluted with the cell culture medium to appropriate concentrations. 
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2.5.1. Growth curve determination 
Knowledge about the growth state of a cell line and its kinetic parameters is 
important in designing in vitro experiments using the cell line. Therefore, the growth 
cycle of LLC-PKl cells was determined by direct counting the cell number following a 
certain time of incubation at various seeding densities in multi well plates. The procedure 
is as follows: 
1. After LLC-PKl cells grown to confluent in plastic culture flasks, they were 
trypsinized with 0.25% trypsin-EDTA solution to prepare single cell suspension. 
2. Three concentrations of cell suspension lxlO\ 3x104, and lx105 cells/mL in 25 mL 
of medium was prepared. 
3. Cells were seeded in a 24-well plate at each concentration, with 1 mL!well. Cell 
suspension was added slowly from the center of the wells, so that the cells do not 
swirl and achieve even distribution of cells. 
4. Plates were placed in a humidified 5% C02 incubator without stirring the cell 
suspensiOn. 
5. After 24 h incubation, medium was removed completely from three wells in each 
plate; the cell monolayer was washed three times with PBS; 200 ~-tL of 0.25% 
trypsin-EDT A solution was added into each of the wells; the plate was incubated 
for 15 min at 37 °C; cells were then dispersed with a pipette thoroughly in trypsin-
EDT A and counted with a hemocyctometer. 
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6. Plates were returned to the incubator as soon as the cell samples in trypsin were 
removed. 
7. Sampling was repeated every 24 h until the stationary phase was reached. The 
medium was changed every three days or sooner depending on their growth. 
2.5.2. MTT assay 
Cytotoxicity of CsA in LLC-PKl cells was determined using the MTT assay. IC5o 
was defined as the concentration of CsA causing 50% inhibition of cell growth. 
The MTT assay is based on the enzymatic reduction of a yellow, water-soluble 
tetrazolium dye (MTT) in living, metabolically active cells, but not in dead cells. The 
reaction is carried out in 96-well plate, and produces a purple-colored formazan soluble 
in DMSO, which can be measured colorimetrically using a microplate reader. 
Basically, the procedure used in this study was identical to the assay described by 
Ford [Ford and Richardson, 1989], which is a modification of a method described 
originally by Mosmann [Mosmann, 1983]. 
MTT was dissolved in PBS at a concentration of 5 mg/mL as a stock, sterile 
filtered and stored in a dark environment at 4 OC for up to three weeks. 
LLC-PKl cells were grown at 37 OC in a humidified atmosphere of 95% air and 
5% C02 in plastic culture flasks to confluence. To find a proper range of cell density for 
which absorbance at 570 nm versus cell density is linear, the cells were trypsinized with 
0.25% trypsin-EDTA solution to prepare single cell suspension in medium at 2.6x106 
cells/mL. A 96-well plate was filled entirely with 100 t-tL/well medium, to which 100 IlL 
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of the cell suspension was added into eight wells of the first column, and the cells were 
titrated 100 j.tL/well by two-fold serial dilutions across the plate using a multichannel 
pipette, i.e., titrated 100 J,tLiwell cell suspension with a multichannel pipette from the 
wells of Column 1 into wells of Column 2 containing 100 J,tLiwell medium, and mix the 
cell suspension thoroughly. Then transfer 100 J,tLiwell of the two-fold diluted cell 
suspension from these wells into the next wells of Column 3 containing 100 j.tLiwell 
medium. This step was repeated till Column 11. Wells of Column 12 containing only 
medium was served as blank. After the plate was incubated at 37 OC for 24 h, 50 j.tL of 
medium was added into each well, followed by additional 48 h incubation. Then medium 
was aspirated and 100 j.tL ofMTT solution (0.5 mg/mL) was added to each well. After 4 
h incubation with MTT at 37 OC, the supernatant was carefully aspirated, and then 100 j.tL 
of DMSO was added to each well. The plate was agitated on a plate shaker for 20 min at 
room temperature, then read spectrophotometrically at 570 nm with 630 nm as reference 
wavelength by a microplate reader. 
To choose a proper concentration of seal oil emulsion that is not toxic to the LLC-
PKl cells, a single cell suspension at 2x 104 cells/mL was seeded 50 J,tLiwell into a 96-
well plate. After incubation at 37 OC for 24 h, 100 j.tL of various concentrations of seal oil 
emulsion (0.000032%-0.004%) was added to the plate, followed by 24 h incubation. 
Then the medium was aspirated, MTT solution (0.5 mg/mL) was added and the plate was 
incubated for an additional 4 h, and finally DMSO was added to the cells after removal of 
MTT solution to read absorbance at 570 nm. Cells incubated only in medium were used 
as a control; Wells containing 0.004% seal oil emulsion with no cells served as blank:. 
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To determine the IC50 value of CsA under the current experiment condition, a 
LLC-PKl single cell suspension at a density of 2xl04 cells/mL was seeded 50 ~J.Liwell 
into 96-well plates using a multichannel pipette. The plates were incubated at 37 OC for 
20 h to allow cells to reattach and re-equilibrate, followed by addition of 50 !J.L of 
medium and incubation for 4 h. Without removing any medium, 50 ~J.Liwell of various 
concentrations of CsA (0, 1.88, 3.75, 7.5, 15.0, 30.0 11M) in medium were added to the 
plate. After 24 h incubation with CsA, the medium was aspirated from each well and 
MTT solution (0.5 mg/mL) was added for additional 4 h incubation, and finally DMSO 
was added to read absorbance at 570 nm. Wells containing medium in combination with 
10 J.lM CsA (final concentration) but no cells were used as blank. Results were expressed 
as a percentage of the absorbance of the control, and IC5o values were calculated. 
The effect of DHA, EPA and V E on the cytotoxicity of CsA was also determined 
using the MTT assay, respectively. As stated above, LLC-PKl cells were incubated in 
96-well plates for 20 h, then 50 !J.L ofvarious concentrations ofDHA (0.24-30 ~J.M), EPA 
(0.3-30 j.!M) or VE (0.3-30 J.lM) in cell culture medium (three times the final 
concentration) were added to each well, respectively, followed by 4 h incubation. Then 
50 !J.L of 10 J.lM CsA (final concentration: 3.3 j.!M, IC50) was added to each well. After 24 
h incubation following drug exposure, the cells were incubated with MTT solution (0.5 
mg/mL) for 4 h, and then added DMSO to read absorbance at 570 nm. 
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2.5.3. Measurement of cytotoxicity by lactate dehyd:rogensae (LDH) leakage 
Cytotoxicity was also assessed using an indicator of membrane lysis. LDH is a 
stable cytoplasmic enzyme found in most cells, leaking out upon damage of the cell 
membrane [Welder, Acosta, 1994]. The release of intracellular LDH to the extracellular 
medium was measured by determining the activity of this enzyme using a LDH 
Cytotoxicity Detection Kit. The principle of this enzymatic test is that lactic acid is 
converted to pyruvic acid by catalysis ofLDH, with NAD+ reduced to NADH I H+. In the 
second step, H/H+ is transferred from NADH/H+ to tetrazolium by the catalyst 
diaphorase to form formazan, a red colored substance whose absorbance can be read 
colorimetrically at 450 nm [Cook, Mitchell, 1989; Goergen eta!., 1993]. 
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Briefly, LLC-PKl cells were seeded and incubated in 96-well plates in M199 
supplemented with 1.5% serum (it is suggested to conduct the assay with low serum 
concentration to minimize background absorption) in the presence or absence of 0.0001% 
seal oil emulsion for 24 h. Then the cells were exposed to various concentrations of CsA 
(final concentrations: 0-10 11M) and incubated for another 24 h. At the end of the 
incubation, the 96-well plate was centrifuged at 250 g for 10 min. The supernatant in 
each well was carefully transferred (1 00 11Liwell) into corresponding wells of another 
optically clear flat bottom 96-well plate. Each well was then added 100 11L of the reaction 
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mixture and the plate was incubated at room temperature for 30 min. During this 
incubation, the plate was protected from light. The absorbance in each well of the plate 
was read at 490 nm by a microplate reader. 
The effects ofDHA and VE on CsA-induced LDH release in LLC-PK1 cells were 
also tested, respectively. Various concentrations of DHA (final concentration: 0.08-10 
J.lM) or V E (final concentrations: 0.1-10 J.lM) were added to the cells 4 h prior to the 
exposure to CsA, and coincubated with 3.3 J.lM CsA for 24 h. The supernatants were 
collected to measure LDH levels the same as stated above. 
2.5.4. Measurement of lipid peroxidation in CsA-treated LLC-PKl cells 
The effect of EPA, DHA or V E on lipid peroxidation in the process of CsA-
induced cytotoxicity in LLC-PKl cells was also studied. The content of lipid 
peroxidation product, MDA, in the cell lysate was determined by TBARS assay. 
LLC-PK1 single cell suspension was prepared by trypsinization with 0.25% 
trypsin-EDTA solution, and seeded in two 24-well plates at 3x104 cells/mL, 1 mL/well. 
After incubation at 37 OC for 24 h, various concentrations (final) of EPA (0.01, 0.1, 1 
1-1M), DHA (0.01, 0.1, 1, 10 J.lM), or VE (0.1, 1, 10 J.lM) were added to the cells and 
incubated for 4 h, respectively. Then 3.3 and 6.7 J.lM CsA (final concentration) were 
added to each plate, respectively, followed by coincubation for 24 h. To one well in each 
plate, which carries no cell, was added medium and 3.3 or 6.7 J.lM CsA to serve as blank. 
Cells incubated only with medium without drug treatment were used as normal control. 
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To release the cytoplasmic MDA, 2% Triton X-100 (final concentration) was 
added to each well to lyse the cells. After most of the cells were found lysed under a 
microscope, the plates were centrifuged at 1,000 rpm, 4 °C for 5 min. MDA content in 
the cell lysate supernatant was measured using TBARS assay as described in Section 
2.4.1 0. The MDA levels were presented as nmol/ mg protein. 
2.6. Statistical analysis 
Data of the in vivo study, effect of dietary supplementation of different oils on 
CsA-induced nephrotoxicity in rats (n= 6-8), were averaged within groups and presented 
as mean ± SD. All in vitro experiments were repeated at least twice with three to five 
replicates. The results were expressed as mean± SD. Statistical analysis was performed 
using unpaired Student's t test. A P value less than 0.05 was considered statistically 
significant. All the calculations and statistics were performed by using SigmaPlot-2001 
statistical analysis software. 
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Chapter 3e Results 
3.1. Preparation and characterization of CsA emulsions 
The CsA in 10% and 20% of seal oil or com oil emulsions containing 0.3-3.8% of 
Cremophor RH-40 and Tween 80 (2:1) were prepared using high pressure 
homogenization. The particle size of the CsA emulsions was determined by a Delsa 
440SX Zeta Potential Analyzer. It was found that there was no significant difference with 
respect to particle size between CsA in 10% or 20% of seal oil emulsions and CsA in 
10% or 20% of com oil emulsions when the amount of surfactants was kept the same. 
The particle sizes of CsA in seal oil and CsA in com oil emulsions with various 
concentrations ofsurfactants are shown in Figure 3.1. and Figure 3.2., respectively. It can 
be seen that the particle size decreased as the amount of surfactants increased from 0.3 to 
1.5% and further increase in the amount of surfactants did not result in further reduction 
in particle size. The particle size of CsA in 10% and 20% of seal oil emulsions was found 
to be around 340 nm in diameter in the presence of 1.5% or higher amount of surfactants. 
The stability of CsA in seal oil or com oil emulsions was monitored by measuring 
the particle size of the emulsions weekly following preparation for four weeks. The 
results are presented in Table 3 .1., and it can be seen that the particle size of CsA in 20% 
of seal oil or com oil emulsions remained unchanged during the four weeks. 
CsA in 20% of seal oil and 20% of com oil emulsions with 1.5% of surfactants 
(Cremophor RH-40: Tween 80 = 2:1) were used for the following in vivo experiment. 
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Figure 3 .1. Particle size of CsA in 10% and 20% of seal oil emulsions containing various 
concentrations of Cremophor RH -40 and Tween 80 at a ratio of 2:1. 
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Figure 3.2. Particle size ofCsA in 10% and 20% of com oil emulsions containing various 
concentrations of Cremophor RH-40 and Tween 80 at a ratio of 2:1. 
62 
Table 3.1. Particle size of CsA in 20% of seal oil and 20% of corn oil emulsions, 
respectively, determined at different time intervals following preparation * 
Time Particle size in diameter (nm) 
CsA in 20% of corn CsA in 20% of seal 
oil emulsion oil emulsion 
Oweek 331 ± 49 337 ±53 
1 week 346 ±54 333 ±50 
2 weeks 324 ± 42 331 ± 38 
3 weeks 336 ± 32 343 ± 39 
4 weeks 341 ± 37 348 ± 45 
*Both CsA emulsions contained 1.5% ofCremophor RH-40 and Tween 80 at a 
ratio of2:1. 
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3.2. In vivo studies 
3.2.1. The comparison of kidney functions of rats administered with CsA in 20% of 
seal oil emulsion and those administered with CsA in 20% of corn oil emulsion 
Rats (three rats in each group) were administered CsA in 20% of seal oil or CsA 
m 20% of com oil emulsion via p.o. (50 mglkg/day) or i.p. (25 mg/kg/day) route, 
respectively, for 28 days. Various parameters of kidney function were monitored. The 
results of rats given CsA in 20% of seal oil emulsion were compared with those given 
CsA in 20% of com oil emulsion. 
3.2.1.1. The level of BUN following administration of CsA emulsions 
BUN and Clcr are commonly used clinical parameters of renal function. BUN 
levels of the rats measured at day 4, 11, 18 and 28 are shown in Figure 3.3. It can be seen 
that BUN levels increased following oral administration of 50 mglkg/day CsA in both 
seal oil and com oil emulsions in comparison with those administered with NS. The 
increased BUN levels in rats given CsA emulsions indicated impairment of kidney 
function by CsA. However, the mean values of BUN of rats given CsA in 20% of seal oil 
emulsion at day 18, 28 (11.8, 12.8 mmoVL) were lower than those of rats given CsA in 
20% of com oil emulsion (14.0, 13.6 mmoVL). The results suggest that oral 
administration of CsA (50 mglkg/day) in 20% of seal oil emulsion induced less kidney 
functional impairment in comparison with CsA in 20% of com oil emulsion. 
Between the rats given CsA in 20% of seal oil and 20% of com oil emulsions via 
i.p. route, there was no apparent difference found at all time intervals. 
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Figure 3.3. BUN levels in rats measured at day 4, 11, 18, and 28 following p.o. (50 
mg/kg/day) or i.p. (25 mg/kg/day) administration of CsA in 20% of seal oil 
emulsion or CsA in 20% of com oil emulsion, respectively. Data shown are 
mean± SD (n=3). 
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3.2.1.2. The level of Ckr following administration of CsA emulsions 
The level of Clcr reflects the ability of the kidney to remove the metabolic waste 
from the body. The Clcr levels of rats following p.o. (50 mg/kg/day) or i.p. (25 
mg/kg/day) administration of CsA in 20% of seal oil emulsion or CsA in 20% of com oil 
emulsion for 28 days are shown in Figure 3.4. 
It was found that administration of CsA in 20% of seal oil or 20% of com oil 
emulsion via both p.o. and i.p. route for four days apparently resulted in decreased Clcr 
levels in comparison with the control group in which NS was given. With the two groups 
in which CsA emulsions were administered via p.o. route, it was found that the mean Clcr 
levels of rats given CsA in 20% of seal oil emulsion were higher than those given CsA in 
20% of com oil emulsion, suggesting less impaired waste eliminating function of kidney 
in rats given CsA in 20% of seal oil emulsion than those given CsA in 20% of com oil 
emulsion. 
However, there was no apparent difference of Clcr levels following i.p. 
administration of CsA in 20% of seal oil emulsion and 20% of com oil emulsion. 
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Figure 3.4. Clcr levels in rats measured at day 4, 11, 18, and 28 following p.o. (50 
mg/kg/day) or i.p. (25 mg/kg/day) administration of CsA in 20% of seal oil 
emulsion or 20% of com oil emulsion, respectively. Data shown are mean ± 
SD (n=3). 
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3.2.1.3. The level of urinary NAG following administration of CsA emulsions 
Urinary NAG is a sensitive indicator of renal tubular cell injury. The urinary 
NAG levels following p.o. (50 mg/kg/day) or i.p. (25 mg/kg/day) administration of CsA 
in 20% of seal oil or 20% of com oil emulsion were determined at day 4, 11, 18 and 28, 
respectively. The results are shown in Figure 3.5. It was found that the urinary NAG 
levels were markedly elevated following administration of CsA for 11 dyas, which were 
consistent with the change of BUN. 
On day 28 the NAG levels followingp.o. administration ofCsA in 20% of seal oil 
and 20% of com oil emulsions were found to be 2. 7 and 4 times of that of the control 
group. Urinary NAG levels in rats given CsA in 20% of seal oil emulsion were much 
lower than those given CsA in 20% of com oil emulsion at both day 18 and 28. 
A similar trend was observed with the two groups where CsA emulsions were 
given via i.p. route. The NAG levels in rats administered with CsA in 20% of seal oil 
emulsion were found to be lower than those given CsA in 20% of com oil emulsion. The 
results indicated that bothp.o. and i.p. administration ofCsA in 20% of seal oil emulsion 
induced less renal tubular toxicity in rats than those of CsA in 20% of com oil emulsion. 
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Figure 3.5. Urinary NAG levels in rats measured at day 4, 11, 18, and 28 followingp.o. 
(50 mglkg/day) or i.p. (25 mglkg/day) administration of CsA in 20% of seal 
oil emulsion or 20% of com oil emulsion, respectively. Data shown are mean 
± SD (n=3). 
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3.2.1.4, The level of SBP following administration of CsA emulsions 
Hypertension is one of the side effects of CsA. Therefore, the SBP of rats was 
monitored prior to and at day 8, 15, 22 and 27 following p.o. (50 mglkg/day) or i.p. (25 
mglkg/day) administration of CsA in 20% of seal oil or 20% of com oil emulsion. The 
results are shown in Table 3.2. It is clear that bothp.o. and i.p. administration of CsA in 
20% of seal oil or 20% of com oil emulsion resulted in an increase of SBP in comparison 
with the control group. The mean SBP level increased to 152 mmHg following oral 
administration of CsA in 20% of com oil emulsion at day 8, compared to 125 mmHg of 
the control group, and the increase persisted throughout the entire experiment. The mean 
SBP in rats given CsA in 20% of seal oil emulsion via p.o. route was found to have 
increased to 158 mmHg at day 8, following which it was decreased at day 22 and 27 to 
131 and 123 mmHg, respectively. 
In the two groups where CsA was given via i.p., SBP increased continuously 
during the course of i.p. administration of CsA in 20% of com oil emulsion, with SBP 
being 165 and 153 mmHg at day 22 and 27; whereas the mean SBP in rats receiving i.p. 
administration of CsA in 20% of seal oil emulsion was found to be lower, with SBP 
being 147 and 137 mmHg at day 22 and 27, respectively. 
The results suggested less vascular toxicity in rats receiving CsA in 20% of seal 
oil emulsion than those receiving CsA in 20% of com oil emulsion via both p.o. and i.p. 
routes. 
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Table 3.2. SBP in rats measured at day 8, 15, 22, and 27 followingp.o. (50 mg/kg/day) or 
i.p. (25 mg/kg/day) administration of CsA in 20% of seal oil emulsion or CsA 
in 20% of com oil emulsion, respectively. 
~ NS p.o. CsAin p.o. CsA in i.p. CsA in I i.p. CsA in 20% seal oil 20% com oil 20% seal oil 20% com oil e 
Day8 130±15 158±20 152±24 136±14 147±19 
Day 15 129±15 155±21 151±15 151±20 156±23 
Day22 125±12 131±17 152±21 147±21 165±24 
Day27 118±13 123±16 147±22 137±18 153±20 
Note: Data shown are mean± SD (n=3). 
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3.2.1.5. The CsA concentrations in blood following administration of CsA emulsions 
At the end of the 28-day CsA administration, the CsA concentration in blood was 
measured by radioimmunoassay. The results are presented in Figure 3.6. 
The CsA concentrations following oral administration of CsA (50 mg/kg/day) in 
20% of seal oil and CsA in 20% of com oil emulsion were found to be 3816 ± 523 and 
4083 ± 1226 J.lg/L, respectively. The CsA concentrations in blood following i.p. 
administration of CsA (25 mg/kg/day) in 20% of seal oil emulsion and CsA in 20% of 
com oil emulsion were found to be 3018 ± 1195 and 3063 ± 415 J.lg/L, respectively. 
Oral administration of CsA at 50 mg/kg/day resulted in a higher concentration of 
CsA in blood than i.p. administration of CsA at 25 mg!kg/day. There was no significant 
difference between the two groups given CsA in 20% of seal oil emulsion and CsA in 
20% of com oil emulsion with the same dosage and administration route. The results 
showed a large variation among individual rats within each group. 
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Figure 3.6. CsA concentrations in blood in rats following p.o. (50 mg/kg/day) or i.p. (25 
mg/kg/day) administration of CsA in 20% of seal oil emulsion or CsA in 
20% of com oil emulsion, respectively, for 28 days. Data shown are mean ± 
SD (n=3). 
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3,2,2, The effect of dietary supplementation of seal oil on the nephrotoxicity induced 
byCsA 
Although the first in vivo experiment showed some interesting and promising 
findings, the significant effects of the seal oil emulsion formulation on the reduction of 
kidney impairment induced by CsA was not clearly demonstrated. This may be due to the 
insignificant supplementation of seal oil from the 20% of seal oil emulsion, as rats were 
still taking large quantity of vegetable oil from their regular chow diet. To eliminate the 
effect of dietary fat intake on the experimental results, the second in vivo experiment was 
designed so that the animal diet was carefully controlled in order to reflect the effect of 
seal oil. 
Rats were randomly divided into four groups and were fed two different diets 
(one with predominantly seal oil and the other with only sunflower oil) we prepared for 
four weeks, followed by i. v. administration of NS or CsA (Sandimmune IV®, 15 
mg/kg/day), respectively, for four weeks, while the rats were still kept on their respective 
diets. 
Various parameters of kidney function were assessed. The effect of seal oil on the 
toxicity induced by CsA was determined by comparing the results of rats fed seal oil 
enriched diet and those fed regular diet containing sunflower oil. 
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3.2.2.1. The level of BUN following i. v. administration. of CsA or NS 
As mentioned in Section 3.2.1.1, BUN and Clcr are commonly used clinical 
parameters of renal function. BlJN levels were measured one week prior to and once a 
week following the start of i. v. administration of CsA (15 mglkg/day) or NS. The results 
ofBUN levels are shown in Figure 3.7. 
BUN levels in the two groups of rats administered CsA for one week were found 
to be higher than those of rats which did not receive CsA. The elevated BUN levels were 
found to be more significant (P<O.Ol) as CsA administration continued, especially in rats 
fed sunflower oil diet. The BUN levels in rats fed seal oil diet at week 3 and 4 were found 
to be lower than those in rats fed sunflower oil diet, and the difference of BUN levels 
between these two groups was significant (P<0.05) at week 4 of CsA administration. The 
baseline BUN value of rats was found to be 17.58 ± 2.26 mg/dL, and the BUN levels 
following four weeks of CsA administration were found to be 33.85 ± 9.50 and 45.73 ± 
7.27 mg/dL in rats on seal oil diet and sunflower oil diet, respectively, suggesting less 
renal functional impairment induced by CsA in rats maintained on seal oil diet than those 
maintained on sunflower oil diet. 
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Figure 3.7. BUN levels in rats measured one week prior to and once a week during the 
i.v. administration ofNS or CsA (Sandimmune N®, 15 mg/kg/day) for four 
weeks. Rats were fed seal oil diet or sunflower oil diet for four weeks prior 
to and during the four-week i. v. administration of NS or CsA. Data shown 
are mean ± SD (n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2,2.2. The level of Clcr following i. v. administration of CsA or NS 
The level of Clcr which reflects the rate of eliminating metabolic waste by kidney 
from blood to urine in rats was measured one week prior to and once a week during the 
i.v. administration of CsA (15 mglk:g/day) for four weeks. The results are presented in 
Figure 3.8. 
It can be seen that the changes of Clcr following the administration of CsA were 
consistent with those of BUN. Clcr levels were found to have decreased in rats 
administered with CsA (both rats fed seal oil diet and rats fed sunflower oil diet), 
compared with the control groups where NS was given. Following two weeks of i. v. 
administration ofCsA (15 mglk:g/day), the Clcr ofrats fed seal oil diet and sunflower oil 
diet were found to be 0.95 ± 0.24 and 0.93 ± 0.25 mL!min, respectively, significantly 
decreased in comparison with 1.50 ± 0.37 and 1.49 ± 0.28 mL/min in the control groups. 
The reduced Clcr continued into week 3 and 4. However, at week 3 and 4, the reduction 
of Clcr levels in rats fed seal oil diet seemed to be less significant than those in rats fed 
sunflower oil diet, and the difference of Clcr levels between the two groups became 
significant (P<0.05) at week 4 of CsA administration. 
The decreased Clcr levels in rats given CsA clearly indicated the kidney 
functional impairment induced by CsA administration. Rats maintained on seal oil diet 
for eight weeks showed less renal functional impairment in comparison with those 
maintained on sunflower oil diet at week 3 and 4 of i. v. administration of CsA (15 
mglk:g/day). 
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Figure 3.8. Clcr levels in rats measured one week prior to and once a week during the i. v. 
administration of NS or CsA (Sandimmune IV®, 15 mg/kg/day) for four 
weeks. Rats were fed seal oil diet or sunflower oil diet for four weeks prior 
to and during the four-week i. v. administration of NS or CsA. Data shown 
are mean ± SD (n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#p<Q.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2.2.3. The volume of urine excreted in 20 b. following i. v. administration of CsA or 
NS 
Since the main function of the kidney is to excrete and condense urine, urine 
volume within a certain period of time is an indicator of kidney function. The volume of 
urine collected over 20 h using metabolic cages was measured one week prior to and 
once a week during the i.v. administration ofCsA (15 mglkg/day). The results are shown 
in Figure 3.9. 
It can be seen that rats fed with either seal oil diet or sunflower oil diet 
demonstrated increased urine volume following the administration of CsA (15 
mglkg/day) during the course of the experiment. The average baseline urine volume prior 
to the administration ofCsA was 10.5 ± 4.7 mL/20h, which was increased to 33.4 ± 19.3 
and 50.0 ± 14.5 mL/20h in rats maintained on seal oil and sunflower oil diets, 
respectively, at week 4. Rats, following administration of NS, did not demonstrate 
significant change in urine volume. Following administration of CsA, the mean urine 
volume of the rats maintained on seal oil diet was significantly lower than that of the rats 
kept on sunflower oil diet at all time intervals except for the first week, suggesting less 
interruption of the renal tubular reabsorption function in rats maintained on seal oil diet 
for eight weeks. 
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Figure 3.9. The volume of urine collected over 20 h from rats one week prior to and once 
a week during the i.v. administration ofNS or CsA (Sandimmune IV®, 15 
mglkg/day) for four weeks. Rats were fed seal oil diet or sunflower oil diet 
for four weeks prior to and during the four-week i. v. administration ofNS or 
CsA. Data shown are mean± SD (n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2,2.4. The amount of protein excreted in urine following i. v. administration of CsA 
orNS 
The amount of protein excreted in urine within a certain period of time is an 
indicator reflecting the reabsorption function of kidney. The amount of protein in the 
urine was assessed by analyzing the protein content in the urine samples collected over 
20 h from rats during i. v. administration of CsA (15 mglkg/day) for four weeks. The 
results are compared with those obtained from rats administered NS. The protein amounts 
found in the urine samples of rats kept on seal oil diet or sunflower oil diet are shown in 
Figure 3.10. 
It was found that following i. v. administration of CsA the protein excretion in the 
urine samples collected over 20 h rose significantly (P<0.05) in rats both kept on seal oil 
diet and on sunflower oil diet when compared with rats administered with NS. The 
protein excretion levels in the urine of rats fed on seal oil diet and sunflower oil diet 
following the administration ofNS were comparable, 41.0 ± 9.1 and 49.0 ± 20.5 mg/20h, 
respectively. The protein excreted in the urine of rats fed on seal oil diet and sunflower 
oil diet following i. v. administration of CsA were 70.8 ± 26.5 and 85.4 ± 45.1 mg/20h, 
respectively. 
The results indicated that the reabsorption of filtered protein by kidney was 
decreased following i. v. administration of CsA (15 mglkg/day) for four weeks. However, 
rats maintained on the seal oil diet had lower protein content in urine, i.e. better 
reabsorption than those maintained on sunflower oil diet. 
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Figure 3.10. The protein excretion levels in urine samples collected over 20 h from rats 
following i. v. administration of NS or CsA for four weeks. Rats were fed 
seal oil diet or sunflower oil diet for four weeks prior to and during the four-
week i.v. administration of NS or CsA (Sandimmune IV®, 15 mg!kg/day) 
for four weeks. Data shown are mean± SD (n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2.2.5. The urinary NAG levels following i. v. administration of CsA or NS 
As mentioned previously, urinary NAG is a sensitive indicator of renal tubular 
cell injury. NAG levels in the urine samples of rats were measured one week prior to and 
once a week during the i. v. administration of CsA (15 mglkg/day) for four weeks. The 
results are shown in Figure 3.11. 
The changes of urinary NAG levels following the i. v. administration of CsA were 
similar to those of BUN. Urinary NAG levels were found to have increased in rats 
administered with CsA (both rats fed seal oil diet and rats fed sunflower oil diet), 
compared with their respective control groups where NS was given. The elevation of 
urinary NAG levels in rats appeared significant (P<O.Ol) following two weeks of 
administration of CsA and continued throughout the entire experiment. Especially in rats 
maintained on sunflower oil diet, the value increased almost three times from the baseline 
of 9842 ± 1318 to 26755 ± 2817 1-1mol/h/L at week 4. However, the urinary NAG levels 
in rats maintained on seal oil diet were lower than those of rats on sunflower oil diet at all 
time intervals during CsA administration, and the difference became significant by the 
third week of CsA administration, suggesting less renal tubular toxicity induced by i. v. 
administration of CsA in rats maintained on seal oil diet than those on sunflower oil diet. 
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Figure 3.11. Urinary NAG levels in rats measured one week prior to and once a week 
during the i.v. administration of NS or CsA (Sandimmune IV®, 15 
mglkg/day) for four weeks. Rats were fed seal oil diet or sunflower oil diet 
for four weeks prior to and during the four-week i.v. administration ofNS or 
CsA Data shown are mean ± SD (n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2.2.6. Kidney histological changes following i. v, administration of CsA or NS 
At the end of the four-week i.v. administration ofNS or CsA (15 mglkg/day), the 
rats were sacrificed, the left kidneys of rats were taken and kidney slides were prepared 
for histological analysis. 
Light microscopic examination of kidney slides found no morphological changes 
between rats maintained on seal oil diet and sunflower oil diet following the i. v. 
administration of NS. However, focal alterations within the proximal tubule in rats 
administered CsA were observed. Most notably, the presence of numerous intracellular 
vacuoles was similar to those described in CsA nephrotoxic models [Blair et al., 1982]. 
The abnormality found in rats maintained on seal oil diet following i. v. administration of 
CsA (15 mg/kg/day) for four weeks appeared less severe than that of rats kept on 
sunflower oil diet. In addition, brush border loss and singe cell necrosis were noted in the 
latter. 
Due to the unexpected health condition of the histologist, the morphological 
changes of kidney could not be graded and photos could not be taken as we designed. 
85 
3.2.2. 7. The level of SBP following i. v. administration of CsA or NS 
In order to evaluate if dietary supplementation with seal oil has any effect on 
hypertension associated with the administration of CsA, SBP of rats maintained on both 
seal oil and sunflower oil diets were measured one week prior to and once a week during 
the i.v. administration ofNS or CsA (15 mglkg/day). Results are shown in Table 3.3. 
Increased SBP was observed in rats given CsA as early as one week following the 
start of administration of CsA, and continued throughout the entire course of the 
experiment. The SBP values in rats kept on sunflower oil diet and given CsA were 136.6 
± 9.1, 146.3 ± 4.6, 142.9 ± 3.1, 147.9 ± 7.8, 145.3 ± 8.2 mmHg at week 0, 1, 2, 3, and 4, 
significantly (P<0.01) higher than those of the control, which were 133.5 ± 2.7, 133.2 ± 
4.7, 131.5 ± 6.2, 135 ± 6.1, 127.5 ± 6.0 mmHg, respectively, at corresponding time 
points. 
Compared with the control group where NS was administered, the increase of 
mean SBP levels in rats maintained on seal oil diet following the administration of CsA 
(15 mg!kg/day) was not statistically significant, except for the value at the first week of 
CsA administration (P<0.05). The mean SBP values in rats kept on seal oil diet increased 
less than those in rats kept on sunflower oil diet at all time intervals following the i. v. 
administration of CsA, suggesting dietary supplementation of seal oil is beneficial in 
alleviating the elevated SBP associated with CsA administration . 
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Table 3.3. SBP rats measured one week prior to and once a week during the i. v. 
administration ofNS or CsA (Sandimmune IV®, 15 mglkg/day) for four weeks. 
~ seal oil diet + NS sunflower oil diet seal oil diet + sunflower oil diet injection + NS injection CsA injection + CsA injection I I e 
WeekO 134.7±9.6 133.5±2.7 135.0±8.5 136.6±9.1 
Week 1 130.2±3.7 133.2±4.7 138.8±6.6 # 146.3±4.6 ## 
Week2 133.7±5.9 131.5±6.2 139.3±4.5 142.9±3.1 ## 
Week3 134.7±5.2 135.0±6.1 142.1±11.9 147.9±7.8 ## 
I 
Week4 133±8.8 127.5±6.0 140.7±7.8 145.3±8.2 ## 
Note: The rats were fed seal oil diet or sunflower oil diet for four weeks prior to and 
during the four-week i. v. administration of NS or CsA. Data shown are mean ± SD 
(n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ CsA 
injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3,2.2.8. The body weight (BW) of rats during the entire experiment 
BW is a commonly used parameter of growth. Rats were fed seal oil diet or 
sunflower oil diet for four weeks, followed by four weeks of i. v. administration of NS or 
CsA (Sandimmune IV®, 15 mglkg/day), respectively, while the rats were still maintained 
on their respective diets. The BW of rats was recorded everyday during the entire 
experiment. 
The mean weekly BW of each group was calculated and the results are shown in 
Figure 3.12. There was no difference with respect to BW among the four groups of rats, 
before the administration of CsA or NS. The mean BW of rats prior to the administration 
ofNS or CsA was 294 ± 17 g. After the first week of administration ofNS or CsA, it was 
found that the rats given CsA showed less BW increase, compared to the rats given NS. 
Moreover, this difference of BW between rats given NS and CsA became significant 
(P<O.Ol) after the second week. At the end of the fourth week, the BW of rats kept on 
seal oil diet or sunflower oil diet and given NS were 451 ± 30 and 455 ± 29 g; while the 
BW of rats kept on seal oil diet or sunflower oil diet and given CsA were found to be 370 
± 14, and 383 ± 18 g, respectively. 
The results indicated that i. v. administration of CsA (15 mg/kg/day) suppressed 
the growth of the rats. There was no difference of growth between rats supplemented 
with seal oil and sunflower oil with administration of CsA or NS. 
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Figure 3.12. Mean BW of rats determined once a week throughout the entire experiment. 
Rats were fed seal oil diet or sunflower oil diet for four weeks prior to and 
during the four-week i. v. administration of NS or CsA (Sandimmune IV®, 
15 mg/kg/day). Data shown are mean± SD (n=6-8). 
*P<0.05, **P<0.01: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2.2.9. The CsA concentrations in blood 
Rats were fed seal oil diet or sunflower oil diet for four weeks, followed by four 
weeks of t.v. administration of NS or CsA (Sandimmune IV®, 15 mglkg/day), 
respectively, while still maintained on their respective diets. Blood was taken by cardiac 
puncture upon sacrifice at the end of the experiment. 
CsA concentrations in the whole blood were measured by LC-MS, and the results 
are presented in Figure 3.13. The CsA concentrations in blood taken 24 h after the last 
dosing of the four-week i. v. administration of CsA were 4417 ± 1003 and 4231 ± 664 
J.!g/L in rats maintained on seal oil diet and sunflower oil diet, respectively. There was no 
statistical difference between them, suggesting dietary supplementation of different oils 
(seal oil and sunflower oil) had no effect on the pharmacokinetics of CsA following i.v. 
administration. 
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Figure 3.13. CsA concentrations in blood taken 24 h after the last dosing of a four-week 
i. v. administration of CsA in rats. Rats were fed seal oil diet or sunflower oil 
diet for four weeks prior to and during the four-week i. v. administration of 
NS or CsA (Sandimmune N®, 15 mglkg/day). Data shown are mean± SD 
(n=6-8). 
* P<0.05, ** P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
91 
3.2.2.10. MDA content in kidney 
MDA, a product of lipid peroxidation, is a parameter often used to monitor the 
involvement of ROS in certain pathological changes. Rats were fed seal oil diet or 
sunflower oil diet for four weeks, followed by four weeks of i. v. administration of NS or 
CsA (Sandimmune N®, 15 mg/kg/day), respectively, while still maintained on their 
respective diets. At the end of experiment, rats were sacrificed and the right kidney was 
excised. Kidney homogenate was prepared. The level of MDA in the kidney homogenate 
was determined by TBARS assay and the results are shown in Figure 3 .14. 
The MDA contents in rats kept on seal oil diet or sunflower oil diet following the 
administration of CsA were significantly (P<0.05) elevated (197.1 ± 37.3 and 208.7 ± 
49.2 nmollmg protein, respectively), compared to those in rats following the 
administration of NS (149.1 ± 41.0 and 149.6 ± 36.1 nmollmg protein, respectively). 
However, there was no statistical significance between the rats fed seal oil diet and those 
fed sunflower oil diet. 
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Figure 3.14. MDA content in kidney tissue in rats kept on seal oil diet or sunflower oil 
diet and administered NS or CsA (Sandimmune N®, 15 mglkg/day) i. v. 
for four weeks. Rats were fed seal oil diet or sunflower oil diet for four 
weeks prior to and during the four-week i. v. administration of NS or CsA. 
Data shown are mean± SD (n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2.2.11. The level ofurina:ry 6-keto-PGF10J TXB2 
6-keto-PGF1a and TXBz are the stable metabolites of PGiz and TXAz, 
respectively. The 6-keto-PGF1a and TXB2 levels in urine samples of rats maintained on 
seal oil diet or sunflower oil diet for four weeks, followed by i. v. administration of NS or 
CsA (15 mg/kg/day), respectively, for four weeks, were measured by EIA. The ratios of 
urinary 6-keto-PGF1a to TXB2 are presented in Figure 3.15. 
The ratios of urinary 6-keto-PGF1a/TXB2 in rats kept on seal oil diet or sunflower 
oil diet following the administration of NS were 1.23 ± 0.33 and 1.01 ± 0.23, 
respectively. The ratios in rats kept on seal oil diet or sunflower oil diet following the 
administration of CsA (15 mglkg/day) for four weeks were 0.53 ± 0.09 and 0.43 ± 0.08, 
respectively, significantly (P<0.01) lower than those administered with NS. The ratios 
were found higher in rats fed seal oil diet than those of rats fed sunflower oil diet, 
following the administration of either NS or CsA. Between the decreased ratios of urinary 
6-keto-PGF1a/TXBz in the two groups given CsA, the rats maintained on seal oil diet had 
significantly (P<0.05) higher value than rats on sunflower oil diet. 
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Figure 3.15. Urinary 6-keto-PGF1a/TXB2 values in rats kept on seal oil diet or sunflower 
oil diet and administered NS or CsA (Sandimmune IV®, 15 mg/kg/day) 
i. v. for four weeks. Rats were fed seal oil diet or sunflower oil diet for four 
weeks prior to and during the four-week i. v. administration of NS or CsA. 
Data shown are mean ± SD (n=6-8). 
*P<0.05, **P<O.Ol: seal oil diet+ CsA injection v.s. sunflower oil diet+ 
CsA injection 
#P<0.05, ##P<O.Ol: NS injection v.s. CsA injection 
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3.2.2.12. The effect of fatty acid compositions of diet on the fatty acid compositions 
of erythrocyte membrane of rats 
The fatty acid compositions from four randomly collected samples of seal oil diet 
and sunflower oil diet were determined using GC. The fatty acid compositions of lipids 
extracted from diets containing 100% sunflower oil (referred as sunflower oil diet), and 
85% seal oil plus 15% sunflower oil (referred as seal oil diet) are presented in Table 3.4. 
It was found that the diets did not differ in the percentage composition of myristic (14:0), 
palmitic (16:0) and stearic (18:0) acids. However, contents of all other fatty acids were 
significantly different (p<O.OOOl). The sunflower oil diet consisted of a higher content of 
linoleic (18:2n6) and oleic (18:1n9) acids, and the total content of ro-6 fatty acids was 
31.31 %; whereas the total content of ro-6 fatty acids in seal oil diet was only 7 .67%. 
However, the seal oil diet had a markedly higher level (17.34%) of ro-3 fatty acids 
including 20:5n3, 22:5n3, 22:6n3; whereas there was no detectable level of any of these 
ro-3 fatty acids found in the sunflower oil diet. 
The phospholipid fatty acid compositions in the erythrocyte membrane of rats fed 
the two different diets for eight weeks were also analyzed to assess the effect of diets on 
the tissue fatty acid composition. The contents of the fatty acids found in the membrane 
ofRBCs are summarized in Table 3.5. 
It was found that rats maintained on sunflower oil diet had a significantly higher 
level of 20:4n6 and 22:4n6 in the erythrocyte membrane than those kept on seal oil diet. 
Rats kept on the seal oil diet had a significantly (p<O.Ol) higher level of palmitoleic 
(16:ln7), vaccenic (18:ln7), 11-eicosenoic acid (20:ln9), and the total amount of ro-3 
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fatty acids was approximately six times higher than that of rats kept on sunflower oil diet. 
The difference of fatty acid compositions in the erythrocyte membrane of rats maintained 
on the two different diets appears to be consistent with the difference of fatty acid 
compositions in the two diets. There was no significant difference of fatty acid 
compositions in the erythrocyte membrane between rats maintained on seal oil diet and 
sunflower oil diet following i. v. administration of either NS or CsA for four weeks. 
The results indicated that the fatty acid composition in the diet plays an important 
role in the fatty acid composition found in the erythrocyte membrane and CsA 
administration had no significant effect on the phospholipid fatty acid compositions of 
the erythrocyte membrane of rats. 
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Table 3.4. Levels of various fatty acids found in the two diets: sunflower oil diet 
and seal oil diet 
Diet 
Fatty acid Seal oil* (n=4) Sunflower oil** (n=4) 
Myristic (14:0) 6.31±2.03 5.26±0.27 
Palmitic (16:0) 8.25±1.21 4.40±0.97 
Palmitoleic (16: ln7) 16.23±0.85 ## 
Stearic (18:0) 1.42±0.12 3.01±0.30 
Oleic (18: ln9) 26.09±1.56 ## 49.36±5.24 
Vaccenic (18:1n7) 3.77±0.22 ## 0.69±0.02 
Linoleic (18:2n6) 7.29±0.64 ## 31.31±4.30 
a-Linolenic (18: 3n3) 0.77±0.05 ## 
11-Eicosenoic (20: 1n9) 5.81±0.20 ## 
Arachidonic (20:4n6) 0.38±0.16 ## 
Eicosapentaenoic (20:5n3) 6.65±0.49 ## 
Docosapentaenoic (22:5n3) 3.09±0.19 ## 
Docosahexaenoic (22:6n3) 6.83±0.74 ## 
L: saturates 15.98 12.67 
L: mono-unsaturates 46.09 50.05 
L: n6 7.67 31.31 
L: n3 17.34 
Values are mean± SD, #P<0.0005; ##P<O.OOOl 
* Seal oil diet consists of 85% seal oil plus 15% sunflower oil. 
** Sunflower oil diet consists of 100% sunflower oil. 
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Table 3.5. Levels of fatty acids found in the erythrocyte membrane ofrats fed the two 
different diets, the seal oil diet and sunflower oil diet a 
Erythrocyte membrane 
Fatty acid Seal oil+NS 1 Sunflower oil+NS 2 Seal oil+CsA 3 Sunflower oil+CsA 4 
(n=6) (n=6) (n=7) (n=8) 
14:0 0.82±0.25 0.84±0.57 0.74±0.20 0.42±0.06** 
16:0 31.11±8.55 23.95±3.33 32.56±2.16 31.13±5.26 
16:1n7 1.38±0.40 0.72±0.40* 1.92±0.46 0.49±0.08** 
18:0 11.90±4.40 11.71±3.96 11.01±0.71 13.19±5.60 
18:1n9 7.22±1.77 6.89±1.17 11.20±1.07 10.68±1.58 
18:1n7 3.37±0.73 2.82±0.36 4.37±0.21 2.47±0.41 ** 
18:2n6 3.99±1.28 5.42±0.95 5.20±0.31 6.29±1.21 
20:1n9 0.56±0.11 0.29±0.21 0.69±0.10 0.32±0.04* 
20:4n6 6.60±3.45 18.62±1.77* 6.56±1.46 14.84±5.15* 
20:5n3 6.90±4.65 0.71±0.59 ** 5.07±1.20 0.32±0.06** 
22:4n6 1.59±0.31 ** 0.17±0.01 1.58±0.53** 
22:5n3 2.05±0.98 0.40±0.11 ** 2.24±0.58 0.38±0.20** 
22:6n3 3.02±1.38 1.31±0.23* 3.48±1.10 0.97±0.18** 
~saturates 43.83 36.50 44.31 46.63 
~mono 12.53 10.72 18.18 11.49 
~n6 10.59 25.63 11.93 22.71 
~n3 12.28 2.42 10.79 1.67 
Values are mean± SD, *P<0.05; **P<O.Ol seal oil diet v.s. sunflower oil diet 
Note: a fatty acids ofless than 0.1% ofthe total are not included. 
1 Rats fed on diet containing 85% seal oil plus 15% sunflower oil for four weeks, followed 
by four weeks of i. v. administration ofNS while still kept on the same diet 
2 Rats fed on diet containing 100% sunflower oil for four weeks, followed by four weeks of 
i. v. administration ofNS while still kept on the same diet 
3 Rats fed on diet containing 85% seal oil plus 15% sunflower oil for four weeks, followed 
by four weeks of i.v. administration of CsA 15 mg/kg/day while still kept on the same 
diet 
4 Rats fed on diet containing 100% sunflower oil for four weeks, followed by four weeks of 
i.v. administration ofCsA 15 mg/kg/day i.v. while still kept on the same diet 
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3.3. In vitro studies 
3.3.1. Growth curve ofLLC-PKl cell line 
The growth curves of LLC-PKl cells seeded at different cell densities: lxl04, 
3x104, and 1x105 cells/mL, in 24-well plates are shown in Figure 3.16 A. It was found 
that LLC-PKl cells seeded at a density of 1x104 cells/mL showed a typical growth curve 
with a lag phase, a log phase (exponential growth period) and a stationary phase. The 
cells entered the exponential growth period after the first day, which lasted for the next 
four to five days. As shown in Figure 3.16 B, there is a linear relationship between cell 
number and time of culture from the second to the sixth day following seeding at 1 x 104 
cells/mL. The curve can be fitted as: 
Ln(cell number)= 8.852 + 0.5704 *Time 
Rsqr = 0.988 
From the equation, the cell Population Doubling Time (PDT) was found to be 
1.22 days (29 h). 
Starting from the seventh day, the growth of cells was found to be leveled off. 
Based on the above results, experiments were conducted using cells from the second to 
the sixth day following subculturing. 
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Figure 3.16. (A) Growth curves of LLC-PKl cells seeded at different cell densities: 
lx104, 3xl04, and lxl05 cells/mL, in 24-well plates for eight days. (B) 
Linear range of cell density versus time following seeding at 1 x 104 
cells/mL. The cell numbers were determined using a hemocyctometer. 
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Prior to using the MTT assay for cytotoxicity, it was necessary to determine a cell 
density range for which absorbance at 570 run upon MTT assay versus cell number 
following a certain time of incubation is linear. 
Cells of a series of two-fold dilutions ranging from 1.3x106 to 2.5x103 cells/mL 
were seeded into 96-well plates and incubated for 72 h. The number of living cells after 
72 h incubation was reflected by the intensity of absorbance at 570 run. The results of 
absorbance at 570 run detected using MTT assay versus various seeding densities are 
presented in Figure 3.17 .A. When the seeding density was higher than 4 x 104 cells/mL 
(ln(cell number) = e10'6), the absorbance at 570 run leveled off, i.e., the conversion of 
MTT dye by living cells is not linearly proportional to the number of cells. As shown in 
Figure 3.17. B, only when seeding density was in the range of 2.5 x103 to 4 x104 
cells/mL, there was a linear relationship between absorbance at 570 run and cell numbers 
after 72 h incubation. 
The linear curve in (B) can be fitted as: 
Abs.s7onm =3.42lx10-2 + 2.084x10-5 *cell-density, 
Rsqr= 0.997 
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Figure 3.17. The relationship between seeding density ofLLC-PKl cells in 96-well plates 
and absorbance at 570 nm by MTT assay after 72 h incubation. (A) The 
absorbance at 570 nm versus seeding density of LLC-PKl cells ranging 
from 1.3 xl06 to 2.5 xl03 cells/mL. (B) The linear range of absorbance at 
570 nm by MTT assay versus seeding density. 
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3.3.2. Determinatimn of cytotoxicity of the seal oil emulsion in LLC-PK1 cell line 
To assess the effect of seal oil on CsA induced cytotoxicity in LLC-PKl cell line, 
it was important to choose a concentration of seal oil emulsion that is not toxic to the 
LLC-PKl cells. 
The cytotoxicity of seal oil emulsion at various concentrations (0.000032% -
0.004%) in the LLC-PKl cell line was determined using the MTT assay. The results are 
shown in Figure 3.18. 
Compared to the control, it is clear that seal oil emulsion of less than 0.0008% 
had negligible effect on the cells. Although the cell viability is lower in the presence of 
0.000032% seal oil emulsion than that in the presence of 0.00016% seal oil emulsion, 
there was no statistical significance. Therefore, 0.0001% seal oil emulsion was used for 
further study. 
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Figure 3.18. Viability of LLC-PKl cells treated with various concentrations of seal oil 
emulsion (0.000032% - 0.004%) for 24 h. The data are presented as the 
percentage of absorbance at 570 nm of the cells treated with various 
concentrations of seal oil emulsion in comparison with that of control. 
* P<0.05; ** P<O.Ol v.s. M199, control 
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3.3.3. The effect of seal oil emulsion on CsA-induced cytotoxicity measured by MTT 
assay 
The cytotoxicity of CsA in the presence and absence of 0.0001% seal oil emulsion 
was detennined using MTT assay in LLC-PK1 cell line. The cells were incubated in the 
presence and absence of 0.0001% seal oil emulsion for 24 h, followed by addition of 
various concentrations (0-10 J..LM) of CsA and incubation for another 24 h. The result of 
one representative MTT assay out of five repeats is shown in Figure 3.19. The curves of 
cell viability versus concentrations of CsA can be fitted into equations using SigmaPlot 
software as follows: 
• In the absence of seal oil, cell viability= 244.0- 92.51 * ln(CsA Cone. + 4.54) 
e In the presence ofO.OOOl% seal oil, cell viability= 109.4- 46.39* ln(CsA Cone.+ 1.21) 
Based on these equations, IC5o values of CsA can be calculated 
e In the absence of seal oil, IC5o = 3.6 J.!M 
• In the presence of 0.0001% seal oil, IC5o = 2.4 J.!M 
The results indicated that when LLC-PK1 cells were exposed to various 
concentrations of CsA for 24 h in the presence of 0.0001% seal oil emulsion, the IC50 
value of CsA was decreased. 
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Figure 3.19. Viability of LLC-PK1 cells treated with different concentrations of CsA in 
the presence or absence of 0.0001% seal oil emulsion for 24 h using MTT 
assay. The data are presented as the percentage of absorbance at 570 nm of 
the cells treated with CsA in comparison with that of control. 
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3.3,4. The effect of seal oil emulsion on CsA-induced LDH .release 
The effect of seal oil emulsion on the toxicity of CsA was also assessed by 
measuring the level of LDH in the cell culture supernatant of LLC-PKl exposed to 
various concentrations of CsA for 24 h. 
One representative result of LDH levels out of five repeats is shown in Figure 
3.20. It is clear that with the increase of CsA concentration, the level of LDH in the cell 
culture supernatant was also elevated. In the presence of 0.0001% of seal oil emulsion, 
the LDH value was higher than that in the absence of seal oil emulsion. 
The results of both cell viability study and LDH levels indicated that in the 
presence of seal oil emulsion, the cytotoxicity of CsA was enhanced. 
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Figure 3.20. LDH levels in the cell culture supernatant of LLC-PKl cells exposed to 
different concentrations of CsA, in the presence or absence of 0.0001% seal 
oil emulsion for 24 h. The LDH levels were presented as values of 
absorbance at 490 nm. 
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3.3.5, The effect of DHA, VE, and EPA on CsA-induced cytotoxicity measured by 
MTT assay 
In vitro models have their limitations. The in vitro studies using LLC-PKl cell 
culture may have underlined the effect of seal oil as the cells lack the proper lipase to 
release the PUF As from their TAGs. If the benefits of seal oil are ascribed to the PUF As, 
it was considered necessary to study the effects of PUF As in the in vitro modeL Lipid 
peroxidation has been recognized as a potential mechanism of toxic cell injury. V E, a well 
known antioxidant, was also used to test its effect on the cytotoxicity of CsA. 
Various concentrations ofDHA (0.08-10 ~-tM), VE (0.1-10 ~-tM) and EPA (0.1-10 
~-tM) were added 4 h prior to exposure to CsA, respectively, and the cells were then 
coincubated with 3.3 ~-tM CsA and each of the substances for 24 h. Cell viability was 
measured using MTT assay and presented as a percentage of that of the control. Results 
are shown in Figure 3.21. and Figure 3.22. 
It was found that incubated with 3.3 ~-tM CsA for 24 h, the viability of LLC-PK1 
cells was suppressed to 54% of that of the cells incubated without CsA. However, cell 
viability was significantly increased in the presence of various concentrations of DHA 
(0.4-10 ~-tM) after coincubated with 3.3 11M CsA for 24 h, in a concentration-dependent 
manner. The similar trend was observed with different concentrations of V E (0.1-1 0 ~-tM) 
in combination with 3.3 ~-tM CsA for 24 h. In the presence of VE, not only the cell 
viability was increased more significantly than that in the presence of DHA in a 
concentration-dependent manner, but also the cell growth was stimulated at a 
concentration of 10 11M of V E· 
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However, there was no significant change of the cell viability observed when 
incubated in various concentrations of EPA (0.1-1 0 !lM) for 4 h prior to and in 
combination with 3.3 !lM CsA for 24 h. (Since the EPA was in 2 months back-order, it 
did not being tested together with DHA and VE). 
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Figure 3.21. Viability of LLC-PKl cells treated with 3.3 ~-tM CsA in combination with 
various concentrations ofDHA (0.08-10 ~-tM) or VE (0.1-10 ~-tM) using MTT 
assay. The data are presented as the percentage of absorbance at 570 nm of 
the cells treated with CsA combining serial concentrations of DHA or V E in 
comparison with that of normal control. Data shown are mean± SD (n=S-8). 
* P<0.05; ** P<0.01 v.s. NC 
# P<0.05; ## P<0.01 v.s. PC 
NC: normal control; PC: positive control; VC: vehicle control; Ve: vitamin E 
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Figure 3.22. Viability of LLC-PKl cells treated with 3.3 j.!M CsA in combination with 
various concentrations of EPA using MTT assay. The data are presented as 
the percentage of absorbance at 570 nm of the cells treated with CsA and 
serial concentrations of EPA (0.1-1 0 j.!M) in comparison with that of normal 
control. Data shown are mean± SD (n=S-8). 
* P<0.05; ** P<O.Ol v.s. NS 
# P<0.05; ## P<O.Ol v.s. PC 
NC: normal control; PC: positive control; VC: vehicle control 
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3,3.6. The effect of DHA and V E on CsA-induced LDH release 
LDH levels in the supernatant of LLC-PKl cells that incubated with various 
concentrations of DHA (0.08-1 0 J.!M) or V E (0. 0 11M) for 4 h prior to and during the 
coincubation with 3.3 11M CsA for 24 h were measured by a colorimetric method using a 
kit. The results are shown in Figure 3.23. 
The effect ofDHA and VE on LDH release is consistent with the improvement of 
cell viability by DHA and VE. Exposure to 3.3 J.!M CsA for 24 h significantly elevated 
LDH release into culture media (P<O.Ol). 0.02% DMSO, the highest concentration of 
solvent that DHA, VE may bring to the culture system, had no influence to LDH release 
compared to control. The elevated LDH levels were decreased significantly when 
incubated with various concentrations of DHA (0.4-1 0 )..LM) or V E (0.1 - 10 )..LM) for 4 h 
prior to and during the coincubation with 3.3 )..LM CsA for 24 h, respectively; and the 
decrease was in a concentration-dependent manner. 
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Figure 3.23. LDH levels in the supernatant of LLC-PKl cells treated with 3.3 J.!M CsA 
for 24 h, in combination with various concentrations ofDHA (0.08-10 !J.M) 
or V E (0.1-1 0 !J.M). The LDH levels were presented as values of absorbance 
at 490 nm. Data shown are mean± SD (n=5-8). 
*P<0.05; ** P<O.Ol v.s. NC 
# P<0.05; # # P<O.Ol v.s. PC 
NC: normal control; PC: positive control; VC: vehicle control; Ve: vitamin E 
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3.3.7. MDA content in LLC~PKl cells treated with CsA in combination with DHA, 
EPA, orVE 
LLC-PK1 cells were first incubated with various concentrations ofEPA (0.01, 0.1, 
1 ~-tM), DHA (0.01, 0.1, 1, 10 J.LM), or VE (0.1, 1, 10 ~-tM), respectively, for 4 h, followed 
by addition of 3.3 or 6.7 JlM CsA (final concentration). The cells were returned to the 
incubator for another 24 h. lipid peroxidation was assessed by measuring MDA content in 
the cell lysate using TBARS assay. The results are presented in Table 3.6. 
It can be seen that the level of MDA in cells was generally low. It was hard to 
draw any conclusion on the relationship between MDA level and CsA concentration. 
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Table 3.6. MDA concentrations in LLC-PK1 cells after being incubated with 3.3 or 6.7 !JM 
CsA for 24 h in the presence ofvarious concentrations of EPA, DHA or VE 
Cone. (!JM) CsAConc. MDAConc. 
(~JM) (mnol /mg protein) 
0 0.053 
Control 3.3 0.018 
6.7 0.049 
0.01 3.3 0.138 
6.7 0.056 
EPA 0.1 3.3 0.105 
6.7 0.093 
1.0 3.3 0.079 
6.7 0.122 
0.01 3.3 0.061 
6.7 0.108 
0.1 3.3 0.220 
DHA 6.7 0.063 
1.0 3.3 0.029 
6.7 0.201 
10 3.3 0.038 
6.7 0.055 
0.1 3.3 0.206 
6.7 0.046 
VE 1.0 3.3 0.022 
6.7 0.049 
10 3.3 0.095 
6.7 I 0.102 I 
* Data presented are average of 2 repetitions 
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Chapter 4e Discussion 
Since its first use in human in 1978 [Caline et al., 1978], CsA has become the 
hallmark of immunosuppressive therapy in organ transplantation. Today, CsA remains to 
be the first line drug in clinical immunosuppressive regimens in organ and tissue 
transplantation. Moreover, CsA has increasingly contributed to effective treatment of 
several autoimmune diseases, such as psoriasis and rheumatoid arthritis, in recent years. 
The major clinical limitations of CsA are its toxicities, especially nephrotoxicity, 
and unpredicted pharmacokinetics following oral administration, which is thought to be 
partially responsible for the toxicities. CsA, a highly lipophilic, poorly water-soluble 
cyclic peptide, initially had been supplied as an olive oil or other vegetable oil solution 
for clinical use. At present, the widely used commercial formulations of CsA, 
Sandimmune® and Neoral®, are microemuslions. Although Neoral® provides improved 
pharmacokinetics, toxicities still remain to be a problem. Many studies have been 
directed towards optimizing the immunosuppressive efficacy of CsA while minimizing 
its toxicities. In this project, we studied the potential of substituting the conventionally 
used vegetable oil with seal oil in the formulation of CsA. Positive results might lead to 
development of a less toxic formulation by substituting the vegetable oil used in the 
currently available products with seal oil as the lipophilic vehicle. 
4.1. CsA in seal oil and corn oH emulsions 
Emulsions are heterogeneous, fine-dispersion system composed of two immiscible 
liquids, i.e., oil and water. Surfactants are included in the formulation of emulsions for 
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stability reasons. As dispersed systems, emulsions are thermodynamically unstable. 
However, when the particle size of the dispersed phase is less than 150 nm, the emulsions 
are optical clear and become thermodynamically stable. They are known as 
microemulsions. Microemulsion can serve as a drug delivery system [Lundberg, 1991]. 
CsA emulsions in seal oil or corn oil in the presence of different amounts of 
surfactants (Cremophor RH-40: Tween 80 = 2:1, w/w) [Mishra et al., 2001] were 
prepared. It was found that the particle size varied with the amount of surfactants present. 
1.5% of surfactants resulted in particle size of around 340 nm and further increase of the 
amount of surfactant did not further reduce particle size. Both CsA in seal oil and CsA in 
corn oil emulsions were prepared using 1.5% surfactants and they were found to be stable 
for at least four weeks, which was the duration of the first in vivo study. 
4.2. The effect of concomitant administration (p.o. or i.p.) of seal oil with CsA on the 
nephrotoxicity induced by CsA 
The predominant function of kidney is filtration of blood to remove the metabolic 
waste through urine, and reabsorption of filtered nutrients, salts and water in appropriate 
proportions to maintain fluid and electrolyte balance in the body. The kidneys filter up to 
180 liters per day, with 98-99% filtrate reabsorbed and the remainder as waste material 
removed. When kidney is in the state of impairment caused by toxic chemicals or other 
interventions, its waste eliminating function will be affected, characterised as elevated 
BUN and serum creatinine levels, and decreased urinary creatinine excretion. BUN and 
Clcr are therefore used clinically in monitoring kidney function. 
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Increased BUN and decreased Clcr levels were observed in rats following 
administration of CsA in seal oil or com oil emulsion at 50 mglkg/day via p.o. or 25 
mglkg/day via i.p. for 28 days, respectively, indicating kidney functional toxicities. 
However, the functional impairments were more apparent in rats given CsA in com oil 
emulsion via p.o. route as compared to their counterparts given CsA in seal oil emulsion. 
NAG, a lysosomal enzyme originating from the brush border of renal proximal 
tubular cells, is released upon cell injury. Urinary NAG is, therefore, a sensitive indicator 
of kidney tubular injury [Flynn FV, et al. 1992]. Increased urinary NAG levels were 
observed in rats given both CsA in seal oil and CsA in com oil emulsions via p.o. and i.p. 
routes, suggesting direct renal tubular damage occurred. However, the urinary NAG 
levels in rats given CsA in seal oil emulsion were lower than those given CsA in com oil 
emulsion, suggesting less renal tubular toxicity when seal oil was simultaneously 
administered with CsA. 
In addition, elevated SBP in rats given both CsA in seal oil and CsA in com oil 
emulsions via p. o. and i.p. routes were observed. However, the levels of SBP increased 
less in rats given CsA in seal oil emulsion than those given CsA in com oil emulsion 
following both administration routes, suggesting less hemodynamic toxicity associated 
with the administration of CsA in seal oil emulsion. 
According to all the parameters monitored, it was found that rats given CsA via 
p.o. route at 50 mglkg/day in com oil emulsion showed the most severe kidney toxicity 
among the four CsA given groups; whereas those given CsA in seal oil emulsion via i.p. 
at 25 mglkg/day showed the least toxicity. 
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Between the two groups given CsA in seal oil and CsA in com oil emulsions via 
i.p. at 25 mg/kg/day, there was no apparent difference found. This may be due to the poor 
absorption of oil following intraperitoneal administration, as fat accumulation in the 
abdominal cavity was observed when animals were dissected at the end of the 
experiment. The benefit of seal oil was therefore not fully materialized. 
Between the two groups given CsA emulsions via p.o. at 50 mg/kg/day, the rats 
given CsA in seal oil emulsion demonstrated less kidney toxicity and hemodynamic 
change in comparison with the rats given CsA in com oil emulsion. The CsA 
concentrations in blood were found to be comparable suggesting that the difference in 
kidney toxicity was not related to the CsA concentrations in blood. The attenuated kidney 
functional impairments and lower SBP observed in rats given CsA in seal oil emulsion 
over those given CsA in com oil emulsion was likely due to the difference between seal 
oil and com oil used in the formulation, i.e., seal oil has a beneficial effect in reducing 
kidney toxicity and elevated SBP induced by CsA. 
However, no statistically significant reduction of CsA-induced nephrotoxicity by 
concomitantly administered seal oil can be claimed from this study, although the 
parameters measured suggested a beneficial effect of seal oil in reducing CsA-related 
nephrotoxicity when given orally together with CsA in comparison with using com oil in 
CsA emulsion. 
It was also found that the CsA concentrations in the blood following respective 
oral administration of CsA in seal oil or com oil emulsions varied from 5108 to 2725 
j.tg/L within the groups. This was in agreement with the clinical observations [Friman, 
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Backman, 1996] that the oral bioavailability of CsA is associated with great inter- and 
intra-individual variations. CsA is known to be extensively metabolized by hepatic and 
intestinal P450 3A4 mixed function oxidation enzyme. Furthermore, the absorbed CsA 
molecules are actively pumped back to the intestinal lumen by P-gp along the intestinal 
wall. These may be responsible for the low and varying bioavailability of CsA following 
oral administration. Therefore, intravenous administration of CsA directly to the systemic 
circulation was chosen for the next experiment. The effect of seal oil on kidney toxicities 
was evaluated by feeding the animal with seal oil enriched diet. 
4.3. The effect of dietary supplementation of seal oil on the nephrotoxicity induced 
byCsA 
Based on the results of the first in vivo experiment, in the second experiment seal 
oil was given to the animals for four weeks prior to the i. v. administration of CsA and 
during the course of administration (four weeks). It has been reported that lipids are well 
absorbed [Sizer, Whitney, 2003]. Thus, seal oil was incorporated into the diet fed to the 
animals. Sunflower oil incorporated diet was used as control. 
4.3.1. Rats' diets 
The two diets used were modifications of the formula of AIN-93 Purified Diets 
for laboratory rodents suggested by the American Institute of Nutrition Ad Hoc Writing 
Committee [Reeves et al., 1993]. AIN-93G diet with 7% fat and 20% protein is 
recommended for young to support growth, pregnancy and lactational phases, while AIN-
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93M diet with lower protein and fat content is recommended for mature rats. Rats of 250 
g and lighter are considered as young and those above 250 g are considered mature. 
Diets were supposed to be adjusted according to their body weight. However, since 
protein content in diet influences BUN level, the diet for growing rats (AIN-93G) were 
used throughout the whole study to minimize variation. 
Sunflower oil is commonly consumed in human diets, primarily as cooking oil. It 
contains predominantly oleic acid (C18:ln9) (49%) and linoleic acid (Cl8:2n6) (31 %) in 
the form of TAG. Because mammals and humans are unable to synthesize fatty acid with 
double bonds more distal from the terminal carbon of the fatty acid than the ninth carbon 
atom, linoleic acid, an essential fatty acid, must be ingested. Therefore, in order to meet 
the requirement for essential fatty acids, even the seal oil enriched diet (referred to seal 
oil diet) contained small amount of sunflower oil with 15% of the total lipid being 
sunflower oil and the rest being seal oil. The amount of ro-6 PUF As in the seal oil diet 
was found to be 7.67% and that of the ro-3 PUFAs was 17.34%, including EPA, DPA and 
DHA; while the amount of ro-6 PUF As in the diet containing 100% of sunflower oil 
(referred to sunflower oil diet) was 31.31% and that of the ro-3 PUF As was not 
detectable. 
Because oils containing multiple double bonds easily undergo oxidation, tert-
butylhydroquinone, an antioxidant, was used in the diets. 
Male SD rats of 3-week old were maintatined on seal oil diet or sunflower oil diet 
for four weeks prior to and during the four-week i. v. administration of NS or CsA (15 
mglkg/day). The rats fed on sunflower oil diet and administered with NS served as the 
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normal control. Rats fed on seal oil diet and administered with NS were found to exhibit 
all parameters comparable to those of the normal control except for urinary excretion of 
eicosanoids, indicating dietary supplementation of seal oil itself had no influence on 
kidney function of rats. 
4.3.2. Kidney :fu:uu:tional alterations 
As stated previously, increased BUN and decreased Clcr levels indicated impaired 
kidney function. One week following the start of the four-week i. v. administration of 
CsA, markedly increased BUN and decreased Clcr levels were observed in rats given 
CsA, indicating CsA-induced nephrotoxicity. It was also noted that during the last two 
weeks of CsA adminiatration, the renal waste eliminating function of rats maitained on 
seal oil diet was not as severely impaired as those of rats kept on sunflower oil diet as 
suggested by the levels of BUN and Clcr. 
The proximal tubule of kidney reabsorbs approximately 50-60% of the glomerular 
filtrate. Essential nutrients including sugars and amino acids, macromolecules (albumin 
and other proteins), and bicarbonate are extensively reabsorbed along the initial length of 
the proximal tubule [Hook, Goldstein, 1993]. In our study, urine volume collected over a 
20-h period was measured once a week and it was found that the i. v. administration of 
CsA (15 mg/k:g/day) dramatically increased the urine volume, suggesting a serious 
interruption of water reabsorption. One of the rats kept on sunflower oil diet even 
excreted 70 mL of urine within 20 h after four weeks of CsA administration. In contrast, 
rats maintained on seal oil diet with CsA dosing had significantly lower urine volume 
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during the last three weeks of CsA administration. Moreover, the amount of protein 
excreted in urine collected over a 20-h period following four weeks of CsA 
administration was also lower in rats on seal oil diet than those on sunflower oil diet, 
suggesting more filtered proteins (mainly albumin) were reabsorbed by proximal tubule. 
Both urine volume and the amount of protein excreted in urine suggested that 
concomitant dietary supplementation of seal oil with CsA administration was beneficial 
in preserving the renal tubular reabsorption function. 
Because of the large volume of fluid entering and being reabsorbed from the 
proximal tubule, the proximal tubule is a target for a wide variety of toxicants including 
CsA. As stated previously, NAG is an enzyme found in the lysosomes of renal proximal 
tubular cells. The molecular weight of NAG is large enough to preclude its passage 
through the normal glomerular basement membrane. Increased excretion of NAG has 
been demonstrated to be more specific for renal tubular pathology [Flynn et al., 1992]. 
Markedly increased urinary NAG levels were observed in the rats on the sunflower oil 
diet following the start of CsA administration in a time-dependent manner, indicating 
serious proximal tubular injury induced by CsA. However, rats maintained on the seal oil 
diet showed a lower level of NAG following the administration of CsA, suggesting a 
beneficial effect of dietary seal oil against the toxic action of CsA to the proximal tubular 
cells. 
All the parameters related to kidney function measured in the in vivo studies 
including BUN, Clcr, the volume of 20-h urine collection and the amount of protein 
excreted in the 20-h urine collection suggested that seal oil appeared to decrease the renal 
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toxicity induced by CsA. The less functional impairment in rats on seal oil diet was also 
accompanied with fewer morphological changes when compared with their counterparts 
on sunflower oil diet. 
However, there have been conflicting results from the literature [Barcelli et al., 
1982; Hansen eta!., 1995; Kooijmans-Coutinho et al., 1996] with respect to the degree of 
benefit of diets with a high content of ro-3 PUF As on renal function. The discrepancies 
between these reports and the present study are likely due to different experimental 
protocols, such as the quality and quantity of oils given to animals and the length of 
experiments, and high individual variability of the disease process. 
4.3.3. Hemodynamic alteration 
It was reported that use of CsA based immunosuppressive regimens could lead to 
increased incidence of hypertension among solid organ transplantation recipients, 
especially among the patients who have undergone heart transplantation, and the 
incidence of hypertension was found to rise from 20% prior to the clinical introduction of 
CsA to 90% after the use of CsA [Olivari et al., 1989; Ventura et al., 1992]. In this study, 
it was shown that one week of intravenious administration of CsA (15 mglk:g/day) 
significantly elevated SBP in SD rats maintained on the sunflower oil diet. This is in 
agreement with previous reports that administration of CsA (Sandimmune, Neoral) in rats 
at 10-30 mglk:g/day for three days or seven weeks was found to have induced 
hypertension [Shimizu et al., 2001; Tavares et al., 2002]. However, rats maintained on 
the seal oil diet showed lower SBP values than those maintained on the sunflower oil diet 
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following the administration of CsA, suggesting less hemodynamic alterarions induced 
by CsA when large portion of seal oil as dietary lipid was simultaneuiously consumed. 
The decrease in renal toxicity and hypertension induced by CsA in rats 
maintained on the seal oil diet did not appear to be associated with the bioavailability of 
CsA. It was shown that i. v. administration of CsA (15 mglkg/day) to rats resulted in 
comparable CsA levels in blood (4416±1003, 4231±664 f.!g/L in rats on the seal oil diet 
and the sunflower oil diet, respectively). The only difference between the two groups is 
the lipid composition in their diets: one is composed of 85% seal oil and 15% sunflower 
oil, and the other is composed of 100% sunflower oil. Our results suggested that 
concomitant supplementation of seal oil with CsA administration is beneficial in reducing 
the renal and hemodynamic toxicities induced by CsA, and the beneficial effects might be 
attributed to the co-3 long chain PUF As in seal oil. 
There have been many reports suggesting that co-3 PUF As exert favorable actions 
against the toxicities associated with CsA in experimental mammals and humans. In 
those studies co-3 PUF As were either provided through dietary supplementation of marine 
oils [Alexander et al., 1998] or using fish oils as the vehicle for CsA administration 
[Elzinga et al., 1987a; Elzinga et al., 1987b]. Attenuation of CsA-induced hypertension 
by co-3 PUF As supplementation has also been reported both in experimental animal 
models [Mills et al., 1992] and clinical trials with organ transplantation patients [Ventura 
et al., 1993; Maachi et al., 1995]. 
129 
4.3.4. CsA arteriolopatb.y 
The pathogenesis of nephrotoxicity and hypertension associated with CsA is 
largely unknown, but a number of studies suggest that CsA alters renal hemodynamics 
after the first dose with an immediate, prolonged but reversible vasoconstriction of 
glomerular afferent arteriole [Myers et al., 1986]. This leads to a reduction in glomerular 
capillary perfusion, which may consequently result in a decrease in transmembrane 
pressure and GFR, and decreased renal plasma flow (RPF) with Na+ retention [Dieperink 
et al., 1986]. CsA nephrotoxicity is characterized by a decrease in GFR, which has been 
observed in both clinical and animal studies [Thomson et al., 1989; Sabbatini et al., 
1988]. In our in vivo studies, the Clcr levels in rats significantly decreased following the 
administration of CsA, suggesting the elevation of renal vascular resistance and the 
consequently decreased blood flow and GFR evoked by CsA. However, the lower levels 
of Clcr in rats supplemented with seal oil than those supplemented with vegetable oil 
implied a protective role of seal oil against the CsA-induced renal arteriolopathy. 
The underlying mechanism of CsA arteriolopathy is still unclear. It had been 
reported that CsA could enhance in vitro platelet aggregation and subsequent TXA2 
release [Kawaguchi et al., 1985]. CsA was also found to increase platelet aggregation by 
reduced PGh production by the vessel wall [Langman, Y atscoff, 1994]. These findings 
suggest the implication of CsA in vascular abnormality and increased risk of progression 
of atherosclerosis. This CsA arteriolopathy affects renal arterioles and glomerular 
capillaries. It has been observed glomerular capillary thrombosis in biopsy specimens 
taken 1 h after surgery from renal transplant patients pretreated with CsA [Pannar et al., 
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1994]. There are also numerous reports of thromboembolic complications occurring later 
in the posttransplant period in CsA-treated renal allograft patients [Vanrenterghem et al., 
1985; Randhawa et al., 1996]. Thus, the renal dysfunction seems to be originated from 
vascular constriction caused by CsA-induced augmentation ofthromboxane production. 
Increased platelet aggregation and thromboxane release have been shown in 
patients and normal volunteers treated with CsA [Grace et al., 1987], suggesting that the 
potential interruption by CsA to vascular tone may occur not only in pathological but also 
in normal conditions. Both systemic and renal vasoconstrictions of CsA may lead to the 
development ofhypertension [Bennett, Porter, 1988; Scherrer et al., 1990]. 
Based on these reports, CsA associated kidney dysfunction to some extent is 
probably related to kidney ischemia induced by vasoconstriction of afferent arteriole and 
glomerular capillary. Therefore, the basic and common pathological pathway of both 
kidney dysfunction and hypertension associated with CsA administration seems to be 
sustained arteriole vasoconstriction which is at least partially caused by interrupted 
production of eicosanoids with CsA treatment, although other mechanisms have also 
been suggested. In view of the similarity of pathogenesis between CsA-induced disorders 
and ischemic cardiovascular diseases, strategies used for prevention and treatment of 
cardiovascular disease may be applied for CsA-induced abnormalities. Marine oil 
supplementation has been proved to exhibit beneficial effects to ischemic cardiovascular 
diseases such as atherosclerosis. Thus, seal oil, a superior source of ro-3 PUF As, might 
favorably affect CsA-related vascular pathological changes. 
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4.3.5. Alteration of eicosanoids production in CsA administration 
Among the postulated mechanisms involved in the vasoconstriction associated 
with CsA treatment, accumulating evidences revealed an important role of eicosanoids 
which may be influenced by dietary fatty acids intake. Therefore, our attention was 
focused on eicosanoids when studying the effects of seal oil rich in ro-3 PUF As on CsA 
related toxicities. 
The prostanoids including PGs and TXs are cyclic eicosanoids [Darlametsos, 
Varonos, 2001]. PGiz and PGEz are vasodilators and potent inhibitors of platelet 
aggregation. Their biological properties are opposite to the effects of TXA2. Within the 
kidney, TXAz can be synthesized by messangial and epithelial cells. It has significant 
effect on renal hemodynamics, and its pathogenic role in some chemical compounds 
induced toxicity is well-known. A physiological balance between the activities of 
vasodilatory PGs and vasoconstrictor TXAz is important in maintaining a healthy 
vascular tone. 
However, following CsA administration, increased production of TXA2 by 
platelets has been reported [Perico et al., 1986; Parra et al., 1998]. On the other hand, 
concomitant administration of a specific TX synthase inhibitor with CsA results in 
attenuation of CsA associated nephrotoxicity without comprom1smg the 
immunosuppressive activity of CsA [Petrie et al., 1990; Gladue, Newborg. 1991]. There 
has also been a conflicting report that Fisher rats given CsA developed nephrotoxicity 
with no change in urinary excretion ofTXB2 observed [Schnabel eta!., 1991]. 
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PGs are well recognized as potential modulators of renal hemodynamics 
[Scharschmidt et al., 1986]. CsA has been reported to reduce the synthesis of 
vasodilatory PGs. Concomitant administration of a vasodilatory PGE1 analogue, 
misoprostol, to rats given CsA not only reduced acute nephrotoxicity but also resulted in 
a reduction of systemic blood pressure [Paller, 1988], suggesting a possible link between 
CsA associated renal and cardiovascular pathogenesis. Moreover, administration of 
nonsteroidal anti-inflammatory drugs inhibiting production of PGs led to augmented 
renal vasoconstriction induced by CsA [Sturrock et al., 1994], suggesting inhibition of 
PGs synthesis may be an important operative mechanism in CsA-induced nephrotoxicity. 
These studies revealed lli1 enhanced production of vasoconstrictor TXs and suppressed 
production of favorable vasodilator PGs associated with the administration of CsA. 
As stated previously, dietary lipids are involved in eicosanoids metabolic 
pathway, and ingested oils containing different classes of PUF As play an important role 
in the production of eicosanoids. Supplementation of seal oil rich in co-3 PUF As (EPA, 
DHA, and DP A) can change the fatty acids composition in tissue. Since co-3 PUF As have 
a higher affinity for COX than the co-6 class, COX would preferentially interact with 
them. Upon biological stimuli, more co-3 PUF As were released to compete with AA 
(20:4n6), through COX pathway producing reduced 2-series but increased 3-series 
prostanoids (see Figure 4.1.). The 3-series PGs are also vasodilator and anti-aggregatory 
agents, whereas TXA3 is inactive [Needleman et al., 1979]. Furthermore, it was found 
that EPA in marine oils decreased TXA2 but increased PGb PGE2 production 
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[Abeywardena et al., 1989]. Thus, seal oil supplementation would lead the eicosanoids 
production which favors vasodilation. 
ffi-6 PUFAs 
AA 
ncox 
PGG2 
t 
PGH2 
/+~ 
PGI2 PGE2 TXA2 
t t 
6-keto-PGF!a TXB2 
ffi-3 PUFAs 
EPA, DHA 
ncox 
PGG3 
~ 
PGH3 
/~~ 
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~ ~ 
6-keto-PGFla TXB3 
Figure 4.1. Metabolism of prostanoids derived from ro-3 and ro-6 PUF As. 
PGI2 is unstable with a half-life of approximately 3 min in vitro [Rais et al., 
1979], and it undergoes spontaneous hydrolysis to 6-keto-PGF1a. TXA2 has a half-life of 
about 30 sec and is rapidly hydrolyzed to its stable, biologically inactive metabolite, 
TXB2. Due to the quick spontaneous hydrolysis of PGI2 and TXA2, the quantitative 
determination of 6-keto-PGF1a and TXBz are accepted as a measure of PGiz and TXA2 
production, respectively [McCann et al., 1981; Fitzpatrick et a!., 1977]. Our data showed 
that rats maintained on seal oil diet and given NS exhibited higher value of urinary 6-
keto-PGF1a/TXB2 than their counterparts on sunflower oil diet, indicating dietary 
supplementation of seal oil resulted in a higher ratio of vasodilator PGs to vasoconstrictor 
TXs production. In this study, administration of CsA significantly reduced this ratio in 
rats maintained on either seal oil diet or sunflower oil diet in comparison with the rats 
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administered NS, which was consistent with a previous report [Morphake et al., 1994]; 
However, between the two groups given CsA, the rats maintained on seal oil diet showed 
a higher value of 6-keto-PGF 1a/TXB2 than those maintained on sunflower oil diet, 
suggesting dietary supplementation of seal oil to some extent counteracted CsA-induced 
decline ofthe ratio of6-keto-PGF1a/TXB2. 
It should also be pointed out that the levels of 6-keto-PGF la and TXB2 measured 
in this study are actually a mixture of6-keto-PGF1a metabolized from PGI2 and PGh, and 
a mixture of TXB2 from active TXA2 plus TXB3 from inactive TXA3, respectively. Due 
to the cross activity, even the monoclonal antibodies used for the determination of PGs 
and TXs by enzymeimmunoassay, do not separate the 2- from the 1- and 3-series of PGs 
and TXs. 
Taking into account that the extent of decreased renal functions was parallel to the 
degree of lowered value of urinary 6-keto-PGF 1a/TXB2, it can be inferred that the ratio of 
6-keto-PGF1a/TXB2 is closely related to renal function. Concomitant supplementation of 
seal oil with CsA administration resulted in partially reserved ratio of urinary 6-keto-
PGF 1a/TXBz and amelioration of the impaired kidney functions induced by CsA. 
Therefore, the beneficial effects of seal oil against CsA-induced kidney toxicity might be 
exerted by counteracting the imbalanced production of vasoactive prostanoids. 
4.3.6. Influence of dietary oils on fatty acids composition of phospholipid 
There were significant changes of phospholipid fatty acid composition m 
erythrocyte membrane in rats maintained on seal oil diet for eight weeks in comparison 
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with those in rats maintained on sunflower oil diet. A major difference was seen in the 
type of phospholipid fatty acids found in the membrane. The total co-6 PUF As (including 
LA (18:2n6), AA (20:4n6) and 22:4n6) in erythrocyte membrane phospholipid in rats 
kept on sunflower oil diet was two times of that in rats kept on seal oil diet; whereas the 
latter had six times higher total co-3 PUF As (including EPA (20:5n3), DP A (22:5n3), and 
DHA (22:6n3)) content with a concurrent decrease in co-6 PUF As than the former. This 
was probably resulted from the competition between the co-6 and co-3 PUF As for the 
desaturation system. In both animals and human, the pathway for biosynthesis of AA 
(20:4n6) and DHA (22:6n3) involves desaturation and elongation of the essential fatty 
acids LA (18:2n6) and ALA (18:3n3), respectively [Innis et al., 1995]. The co-6 and co-3 
PUF As pathways are believed to use the same desaturase enzymes, and desaturation is 
subjected to substrates competition and product inhibition [Innis, 1991]. Thus, if ALA, 
EPA and/or DHA are ingested, desaturation of LA to yield AA can be inhibited. This 
effect had also been found in liver, kidney, and brain [Innis et al., 1995]. Our results of 
fatty acid compositions of the phospholipids extracted from erythrocyte membrane 
showed an obvious shift of ro-6 to co-3 class when seal oil, rich in EPA, DP A and DHA, 
were the main dietary lipid for eight weeks. 
These changes were in agreement with previous reports that diets rich in co-3 fatty 
acids lead to a displacement of ro-6 fatty acids in erythrocyte membrane [Kim et al., 
1992]. More importantly, it has been found that the changes in phospholipid fatty acid 
composition of erythrocyte membra."le are reflective of the changes that take place in cell 
membranes of other tissues or organs including kidney [Gibson eta!., 1984]. Therefore, 
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analysis of the phospholipid fatty acid compositions in RBCs is considered a practical 
and valid method of estimating the changes in other tissues, and was adopted in our 
study. Moreover, dietary supplementation of fish oil altering fatty acid composition in 
various organs including kidney has been reported [Aukema eta!., 1992]. 
The biological effects of dietary fatty acid are the consequences of the 
incorporation of these fatty acids into the cellular structure of different tissues and organs. 
Of all the fatty acids, the co-3 PUF As were the most influenced by diet, especially EPA 
and DHA [Soriguer et al., 2000]. In our study, of the interest is the fact that the alteration 
of fatty acid composition of phospholipids is in conformity with the favorable increase of 
urinary 6-keto-PGF1a/TXB2 ratio, which might have resulted from an increased EPNAA 
ratio of fatty acid composition in renal cell membranes. This may be the original cause of 
the attenuation ofthe CsA-induced toxicities in the rats supplemented with seal oil. 
4.3.7. Lipid peroxidation 
Besides the contraction effect of CsA on renal arterioles, a number of other 
mechanisms and mediators have been proposed to account for the decreased renal 
function associated with CsA administration. There are experimental observations 
reported that CsA caused a time- and concentration-dependent increase of lipid 
peroxidation in hepatic and renal microsomes vitro [Inselmann et a!., 1990]; 
administration of CsA in vivo reduced antioxidant glutathione levels, and glutathione 
depletion increases the susceptibility to cyclosporine-induced liver and kidney injury 
[Inselmann et al., 1994]. Wang et al. used an antioxidant lazaroid to reduce CsA-induced 
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lipid peroxidation both in vitro and in vivo [Wang, Salahudeen, 1994]. These 
experimental data suggested a possible role of reactive oxygen species (ROS) in CsA 
related toxicity. 
The relationship between DHA levels in tissue and oxidative stress is a 
controversial topic [Yavin et al., 2002]. Someone argued that the multiplicity of double 
bonds in the structure of DHA or EPA makes it easily be attacked by ROS during 
oxidative stress [Halliwel, Chirico, 1993]. A DHA-enriched diet increased peroxidation 
products in plasma and several tissues [Song et a!., 2000], whereas rats fed on a diet lacks 
DHA precursors showed less retinal injury after exposure to light [Organisciak et al., 
1999]. However, it was also reported that DHA-supplemented human lymphocytes are 
less vulnerable to hydrogen-peroxide induced oxidative damage [Bechoua et al., 1999]. A 
recent study investigated the dose-dependent effect ofDHA on the redox status ofhuman 
platelets in vitro, and the results showed a biphasic effect of DHA with antioxidant 
effects at low; whereas prooxidant effects at high concentrations [V ericel et al., 2003]. In 
another study, each of the co-3 PUF As ALA, EPA and DHA in combination with dietary 
vitamin E were fed to rats for 22 days to compare their peroxidation effects. The results 
showed that in rats fed either the EPA diet or the DHA diet with an adequate level of 
vitamin E, the extent of lipid peroxidation in liver, kidney and testis were less than 
expected from the relative peroxidizability index. But the suppression of lipid 
peroxidation below the relative peroxidizability index was not with ALA, which has three 
double bonds [Saito, Kubo, 2003]. These latest data suggested potential antioxidative 
effects ofDHA and EPA when supplied together with adequate amount of vitamin E. 
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Our in vivo experiment with rats showed a significant increase of MDA content, 
the lipid peroxidation product, tested by TBARS colorimetric assay in kidney tissue in 
rats given CsA, indicating the enhancement of lipid peroxidation by CsA, which was 
consistent with the literatures. When seal oil was used as the main lipid source in the diet, 
the rats maintained on a seal oil diet with CsA administration showed lower levels of 
lipid peroxidation in comparison with their counterparts on a sunflower oil diet, although 
the MDA content in kidney tissues were still much higher than that in rats given NS. Our 
results agreed with the report that EPA and DHA can suppress lipid peroxidation when 
supplied with adequate vitamin E. Sufficient amount of vitamin mixture was given to the 
rats as a necessary component in our specific rats' diets. 
4.3.8. Growth suppression 
Suppression of body weight gain in rats given CsA appeared one week following 
the start of CsA administration. The difference of body weight between rats given CsA 
and NS became significant at two weeks following CsA administration. Besides 
suppressed body weight gain, there were no other signs of illness during the whole 
observation. The high dose of CsA might have been a factor. Others also reported growth 
suppression by CsA even with a lower dose administered to rats [Ferguson et al., 1993]. 
It should be pointed out that a high dose of CsA was administered to the rat model 
employed in this study to induce toxicity over a relative short term. The relevance of 
using a large dose of CsA for this study could be criticized, since the value of trough CsA 
concentrations in blood were seven to ten times above the upper limit of clinical 
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therapeutic levels. However, our purpose was to examine renal function with reduced 
GFR mimicking clinical patients who rely on CsA for the rest of their lives after organ 
transplantation. V.f e reasoned that relative preservation of kidney function under this 
condition would argue against a direct toxic action of CsA to the kidney. Moreover, the 
amount of seal oil used in this study is hard to achieve in clinical practice. Further studies 
are needed before applying seal oil to clinical setting. 
4.4. In vitro study 
To further investigate the effective components and mechanism of the effects of 
seal oil on CsA-induced nephrotoxicity at the cellular level, in vitro studies were also 
conducted. As suggested by previous reports, CsA toxicity occurs primarily in the 
glomerulus and epithelial cells lining the proximal tubes of kidney [Mihatsch et al., 
1995]. LLC-PKl is a continuous, porcine kidney cell line expressing many characteristics 
of proximal tubule epithelia [Hull eta!., 1976; Gstraunthaler et al., 1985]. It is often used 
as a model of the proximal tubule for the study of renal toxicity. It was reported that in 
the kidney epithelial cell line LLC-PKl, CsA has been shown to cause a loss of cell 
contacts, reduction in brush border integrity, and a disruption of cell-cell adhesion 
[Zimmerhackl et al., 1997]. CsA also inhibited DNA and protein synthesis of LLC-PK1 
cells [Healy et al., 1998]. Therefore, in our study LLC-PKl cell line was chosen as a 
renal proximal tubular model to assess effects of seal oil and various fatty acids on CsA 
cytotoxicity. 
140 
Knowledge about the growth state of a certain cultured cell line and its kinetic 
parameters, is important in the design of in vitro experiments using cultured cells. The 
same cell lines may have different characteristics when they are in the lag phase, the log 
phase (period of exponential growth), and the stationary phase. Cells that have entered 
the stationary phase grow slowly, and have different morphology. They generally tend to 
secrete more extracellular matrix and become more difficult to be trypsinized. Cell 
cultures in the log phase are commonly most consistent and uniform. Therefore, it is 
important to determine which growth state the cells are in. 
It is also important to consider the effects of the duration of an experiment on the 
transition from one state to another. Adding a drug at different growth state may give 
quite different results, due to altered properties [Freshney, 2000]. Therefore, first of all, 
the growth pattern of LLC-PKl cells was determined. Our results showed LLC-PKl is a 
relatively fast growing cell line with a cell population doubling time of 29 h. From the 
second day after seeding at a density of 1 x 104 cells/mL, the cells entered a stable 
exponential growth period, lasting for four to five days. 
The conversion of yellow-colored MTT dye to the purple-colored formazan 
depends on the activity of mitochondrial dehydrogenase, which is NADH and DADPH 
dependent, thus, the amount of MTT conversion is an indicator of cell metabolic activity. 
The absorbance of the purple color of formazan is only linearly proportional to the 
number of metabolic active cells in a certain range when cells were cultured in multiwell 
micro titer plate. Therefore, the prerequisite of using MTT assay is the number of cells at 
the endpoint of experiment still staying in the linear range of cell number to the 
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absorbance of the purple color of formazan. Under our experimental condition, it was 
found when cells seeded at 2.5 x103 - 4 xl04 cells/ mL, there was a linear relationship 
between absorbance of the converted MTT dye at 570 nm and cell numbers following 72 
h incubation, which was the designed duration of this in vitro study. 
The results ofboth cell viability and LDH release from LLC-PKl cells following 
incubation with various concentrations of CsA ranging from 0.63 to 10 !J.M for 24 h 
showed concentration-dependent cytotoxicity of CsA. These were in agreement with a 
previous report which showed direct toxic effects of CsA on established LLC-PKl cell 
model of renal tubules [Zimmerhackl et al., 1997]. The cellular mechanisms of CsA-
induced toxicity in renal proximal tubular cells are still unclear; however, the beneficial 
effects of antioxidative substances suggested the role of ROS in CsA-induced LLC-PKl 
cell injury [Wang, Salahudeen, 1994]. CsA was shown to induce oxidative injury 
probably by disrupting membrane integrity and altering energy status [Massicot et al., 
1994]. Furthermore, CsA has been reported to enhance the generation of hydrogen 
peroxide in cultured hepatocytes [Wolf et al., 1994] and mesangial cells [Perez de Lema 
et al., 1997]. 
Since our in vivo studies indicated that supplementation of seal oil is beneficial in 
reducing nephrotoxicity of CsA, seal oil emulsion was tested in renal epithelial LLC-PK1 
cells. It was found that higher than 0.00016% of seal oil emulsion was toxic to the cells. 
However, in the presence of 0.0001% of seal oil emulsion, which was not toxic to the 
LLC-PKl cells (as demonstrated by MTT assay), enhanced cytotoxicity of CsA in the 
cells was observed after 24 h incubation with various concentrations of CsA, as 
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evidenced by decreased IC50 values of CsA and increased LDH release. Lack of 
beneficial effects of seal oil in the growth of LLC-PKl cells and against the cytotoxicity 
of CsA were likely due to the lack of lipase in the cultured cells which are essential to 
release PUF As from their TAGs. 
To test this postulation, PUF As, DHA and EPA, respectively, were tested in the 
LLC-PKl cells. In addition, a.11tioxidant nutrients (e.g. Vitamins E and C) were found to 
inhibit the synthesis of ROS and TXs, and the lipid peroxidation process induced by CsA 
in kidney structures [Parra eta!., 2003]. Therefore, vitamin E was also tested using LLC-
PK1 cells treated with CsA. Vitamin E (0.1-10 11M) exhibited a beneficial role in a 
concentration-dependent manner as assessed by cell viability and LDH release. DHA (0.4 
-10 11M) also showed a beneficial effect in a concentration-dependent manner on the 
cytotoxicity demonstrated by CsA as evaluated by cell viability and LDH release. 
However, EPA (0.1-10 11M) showed no significant effect on the cytotoxicity ofCsA. 
Vitamin E is a well-known antioxidant that stabilizes cell membranes by 
interfering with lipid oxidation process [Tappel, 1970]. The reduction of CsA-induced 
cytotoxicity in LLC-PKl cells by vitamin E observed in the present study may be 
attributed to the involvement of vitamin E in the inhibition of lipid peroxidation. Our 
results seemed in conformity with the concept that ROS was involved in the process of 
CsA related cytotoxicity. Of the interest is the fact that the action of DHA appeared 
similar to that of vitamin E, i.e. DHA might reduce the cytotoxicity of CsA by the same 
mechanism of inhibiting lipid peroxidation. 
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To investigate the possible mechanism by which DHA exhibited its beneficial 
effect on the cytotoxicity of CsA, the lipid peroxidation product MDA contents in the cell 
culture supernatant were measured by TBARS assay with a spectrofluorophotometer. 
However, due to the low content of MDA in the cell culture supernatant and the limited 
sensitivity of the method, the results were rather inconclusive. More sensitive detection 
methods are needed, such as confocal laser scanning microscopy, as suggested in the 
literature [Nishida et al., 2003]. 
A weak point of this in vitro experiment is that CsA (Neoral®) used is a 
commercial product, the exact components are unknown. Therefore, it is impossible to 
prepare a control to show that any toxicity exhibited by Neoral® does not pertain to 
substances other than CsA in the formulation. 
It has been reported that CsA could be prepared as stock solution by dissolving 
CsA in an organic solvent such as ethanol, DMSO or DMF (around 30 mg/mL), which 
could be diluted using cell culture media [Nishida et al., 2003; Andres, Cascales, 2002). 
In our study, CsA stock solutions in DMSO, DMF and ethanol ranging from 4 - 50 
mg/mL were prepared. However, upon more than 50 times dilution with cell culture 
medium, CsA precipitations were observed under microscope, although the preparations 
were visually clear. CsA at 50-100 JlM was reported to be used for inducing cytotoxicity 
[Nishida et al., 2003; Zimmerhackl et al., 1997]; however, 20 JlM CsA incubated for 24 h 
was found to result in almost 100% cell death in our study. 
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4.5. Other potential roles of DHA against CsA toxicities 
The protective role of w-3 PUPAs in the renal process of CsA is widely believed 
to be ascribed to their effects on eicosanoids metabolism. In addition, there have been 
reports suggesting that marine oils may play a role (in cell membrane) to counteract CsA-
induced physical alteration of cell membrane structure. 
LeGrue et al. [LeGrue et al., 1983] found that there is almost the same binding 
affinity of CsA to lymphocytes and phospholipids which lack a specific binding site for 
CsA. This finding suggested that the toxic effect of the lipophilic CsA to vasculature 
might be exerted because of the physical intercalation into the endothelial cell membrane. 
A number of studies focusing on the interaction of CsA with the membrane bilayers 
showed that CsA caused increased permeability of liposomal membrane to Na+ and Ca2+ 
[Fahr, Seelig, 2001; Wolf eta!., 1998], and decreased membrane fluidity [Rossaro eta!., 
1988]. Another study which studied the effects of CsA on the plasma membrane of 
peripheral blood lymphocytes found that CsA can decrease membrane fluidity in one to 
five minutes after addition "to cultured cells at doses similar to those found in patient's 
blood immediately following intravenous administration [Niebylski, Petty, 1991]. These 
studies revealed that CsA can alter membrane structures by intercalation into the 
membrane bilayer thereby resulting in altered functions. 
On the other hand, when dietary fatty acids are ingested, they can be incorporated 
into the structure of membrane phospholipids, and then can produce mediators for 
biological reactions upon stimuli. DHA, abundant in marine oils, was found to be 
tenaciously retained in tissues [Salem et al., 1986]. When added to membrane bilayers as 
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either a free fatty acid or as part of a phospholipid, DHA can induce major changes in 
membrane fluidity [Ehringer et al., 1990; Simopoulos, 1991] and increase phospholipid 
vesicles and the permeability of cancer cell [Stillwell et al., 1993]. Moreover, DHA was 
also reported to alter membrane protein and receptor functions [Zerouga et al., 1995], and 
change the membrane bilayer thickness [Lee et al., 1986). These alterations rendered by 
DHA in endothelial cell membrane structure could counteract the membrane changes 
caused by CsA. 
According to the literature, due to its ability to alter membrane physical properties 
when incorporated, DHA is potentially beneficial to reverse CsA induced cell membrane 
damage. Thus, EPA and DHA, the main ffi-3 PUF As in marine oils, can counteract the 
toxicities related to CsA from the two different biochemical and physical pathways 
respectively, making concomitant supplementation of marine oils with CsA 
administration theoretically reasonable. However, in the current study we have not 
explored the effects ofDHA on cell membranes. 
4.6. Summary 
Our results suggest that use of seal oil, a superior source of EPA, DP A and DHA, 
reduced CsA nephrotoxicity in vivo and the beneficial effects may be due to its effects on 
biosynthesis of prostanoids, although other mechanisms, such as suppression of lipid 
peroxidation, modulation of cell membrane properties and depression of lipoxygenase 
metabolites, are also possible. 
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